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I.1. LONG NON-CODING RNA 
The central dogma of molecular biology ‘DNA makes RNA makes protein’ is no more. Protein 
coding genes are no longer the largest class of genetically encoded entities in the human 
genome, as a myriad of long non-coding RNAs (lncRNAs) have been sequenced and await 
functional characterization. 
The publication of the first draft of the human reference genome in 20011,2 marked 
the beginning of the post genomic era. With the reference genome at hand, 
researchers began to explore the transcriptome, the part of genome that is 
transcribed into RNA. Until recently, messenger RNAs (mRNA) were thought to be 
the most prevalent and important entities of the human transcriptome. After 
transcription and splicing (Figure 1), these transcripts are exported to the cytoplasm 
where they serve as templates for protein synthesis. About 22,000 genes in the 
human genome produce mRNA transcripts, collectively referred to as protein coding 
genes as their sequences encode the amino acid sequences for a protein. Non-
coding genes on the other hand are not translated into protein; the RNA transcript 
itself or a derivate RNA molecule forms the functional product of the corresponding 
gene. Several thousands of non-coding genes have been discovered and functionally 
described. The majority of the functionally annotated non-coding RNA transcripts 
are further processed into short RNA molecules with diverse functions in genetics. 
MicroRNA (miRNA) and small nucleolar RNA (snoRNA) for instance, are two well 
described classes of non-coding RNA3. 
One of the most surprising discoveries brought about by the spectacular 
advancements in (RNA) sequencing technology is the extensive transcription arising 
from regions previously regarded as genomic wasteland. Both large-scale 
collaborative efforts, such as the ENCODE (Encyclopedia of DNA Elements)4 project 
and the FANTOM (Functional ANnoTation Of the Mammalian genome)5 consortium, 
and smaller projects by individual research groups6-8 have expanded the known 
human transcriptome several times in numbers of transcripts. The great majority of 
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these novel transcripts are long (> 200 nt), multi-exonic and without conserved open 
reading frames (ORFs)6,9. As such they give rise to a new genetic class called long 
non-coding RNAs (lncRNAs). Recently, RNA sequencing of over 7,000 human tumor 
samples revealed more than 90,000 distinct lncRNA genes, making this the largest 
genetic class in the human genome10. 
 
 
Figure 1: Protein coding mRNA versus lncRNA expression. Both mRNA and lncRNA 
are transcribed by RNA polymerase II and can undergo splicing. mRNA subsequently 
binds with ribosomes and is translated to protein. While a protein is here the 
functional entity and not the mRNA, lncRNA is functional in itself often through 
complex secondary structures.  
LncRNA genes resemble their protein coding counterparts in genetic structure. 
Although lncRNA transcripts are on average slightly smaller, they can also be multi-
exonic and subject to alternative splicing6. Even from an epigenetic perspective they 
are very similar. Their promoter and gene body regions exhibit the same chromatin 
modifications associated with RNA polymerase II transcribed protein coding genes11. 
Compared to mRNA, the expression levels of lncRNA are typically lower yet more 
1) transcription
2) splicing
3a) translation 3b) folding
mRNA expression lncRNA expression
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tissue and cell-type specific9. Interestingly, the most extensive lncRNA expression is 
found in the testes6. While protein coding genes are evolutionary well conserved, 
lncRNA genes appear to be the result of more recent evolutionary adaptations as 
their sequence conservation scores are often much lower9. Most importantly, 
lncRNAs lack ORFs that exhibit the evolutionary pattern typically observed for 
protein coding ORFs or any other evidence of protein coding potential6,9. Moreover, 
on the subcellular level, lncRNAs are found to be more nuclear enriched compared 
to protein coding mRNAs4. An observation that is highly suggestive for a function 
that does not require ribosomal translation. 
I.2. LNCRNA FUNCTIONS 
In sharp contrast to the extraordinary rate at which new lncRNAs are being reported, 
the rate at which they are functionally characterized is low. Currently, less than 200 
human lncRNA genes have been functionally studied (181 according to 
lncrnadb.org12 and 191 according to genenames.org13). A surprisingly low number 
considering more than 4,400 lncRNA papers have been published to date. Indeed, 
the majority of publications is focused on just a handful of lncRNAs13. Nevertheless, 
the biological processes in which lncRNAs are known to be involved are numerous 
and diverse. 
DOSAGE COMPENSATION: EARLY EVIDENCE FOR FUNCTIONAL LNCRNAS 
The cellular process where lncRNAs made their debut is X-chromosome inactivation 
(XCI). Without a doubt this is currently the best and most extensively described 
process that shows how lncRNAs can play crucial roles in a cell. XCI is the mechanism 
that balances the gene expression on the X-chromosome between sexes in 
mammals. The role of a non-coding RNA in XCI has been recognized since 1992 when 
a 17 kb lncRNA was found to be exclusively expressed from the inactive X 
chromosome14. Referred to as the X-inactive-specific transcript (XIST), this lncRNA 
appeared to coat the entire inactive X-chromosome (Xi)15. Currently it is recognized 
that XCI requires the interplay between several lncRNAs expressed from the same 
genomic locus (X-inactivation center). The TSIX lncRNA is expressed on the active X-
chromosome (Xa) and prevents inactivation by epigenetic silencing of XIST16. In the 
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absence of TSIX expression XIST recruits chromatin modifying complexes. Together 
with XIST, these complexes spread across the entire chromosome, eventually 
silencing the Xi17.  
EMBRYONIC DEVELOPMENT AND CELL DIFFERENTIATION 
The discovery of pervasive lncRNA transcription in the human HOX loci already 
suggests an important role for lncRNAs in development and differentiation18. This 
role is further confirmed by the finding that the majority of lncRNAs expressed in 
mouse embryonic stem (ES) cells have implications in ES cell transcriptional 
regulation and are associated both with cell differentiation and pluripotency19. 
Indeed, several lncRNAs have been discovered that aid in maintaining the 
pluripotent state and prevent differentiation into specific lineages. The lncRNA LINC-
ROR for instance, was found to be crucial for induced pluripotent stem cell and ES 
cell survival. LINC-ROR is under transcriptional control of the key pluripotency 
transcription factors SOX2, OCT4 and NANOG and probably promotes survival by 
inhibiting the p53 response pathway20. In addition to pluripotency, various lncRNAs 
have been implicated in embryonic development. Morpholino-mediated inhibition of 
the conserved lncRNAs cyrano and megamind in zebrafish embryos results in severe 
but distinct phenotypes. While the cyrano morphant showed many developmental 
defects resulting in an overall body malformation, megamind knockdown resulted in 
specific brain and eye defects, pointing to a role in brain development21. Also in 
other species lncRNAs were found with roles in embryonic development. In mouse 
embryogenesis, two lncRNAs have been implicated in cardiac development. The 
poetically named lncRNA Braveheart (BVHT) has been identified and studied in 
mouse ES cells. BVHT was found to be a key regulator in a cardiac gene network and 
its expression is required for cardiac cell fate22. In vivo evidence for the crucial role of 
lncRNAs in mammalian development was found with the lncRNA FENDRR (Fetal-
lethal noncoding developmental regulatory RNA). Not only were homozygous 
FENDRR mutants embryonic lethal, they showed an impaired heart and body wall 
development23. 
IMPLICATIONS IN DISEASE 
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The currently reported functions of lncRNAs go well beyond dosage compensation 
and development. They have been associated with processes as diverse as immune 
response24, paraspecle formation25 and growth arrest26. Given their central role in 
many cellular pathways it should be no surprise that dysregulation of lncRNAs is 
often associated with disease. LncRNAs have already been implicated in an variety of 
diseases27 including COPD28, AIDS29, Alzheimer’s disease30, cardiovascular diseases31, 
autoimmune diseases32 and cancer. In addition, lncRNAs have been associated with 
rare disorders such as the Beckwith-Wiedemann syndrome33, Angelman syndrome34, 
Klinefelter’s syndrome35 and blepharophimosis syndrome36. 
I.3. LNCRNAS IN CANCER 
Numerous reports on lncRNA involvement in cancer have been published to date, far 
more than any other disease or process27. These reports include both oncogenic and 
tumor suppressive lncRNAs, implicated in many different cancer types (Table 1). Like 
cancer itself, their individual mode of action is diverse. In fact, distinct lncRNAs have 
been associated with all of the hallmarks of tumor biology proposed by Hanahan and 
Weinberg37,38. 
HOTAIR is one of the most frequently described oncogenic lncRNAs to date. Elevated 
expression is found in breast cancer39, colorectal cancer40 and pancreatic cancer41, 
and is associated with poor prognosis and metastasis. Transcribed from the HOXC 
locus, HOTAIR regulates gene expression in trans (unlike other lncRNAs in that locus) 
on many genomic loci including HOXD (the mechanism is further described in section 
I.4)18. Among the genes regulated by HOTAIR are several genes with important roles 
in different aspects of cancer biology39,41. 
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Table 1: A summary of lncRNAs with a published role in cancer. With new cancer 
associated lncRNAs reported on a weekly basis, this list is far from complete.  







CCAL Colorectal cancer42 
FAL1 Ovarian cancer43 
HOTAIR Breast cancer39, colorectal cancer40, pancreatic cancer41 
MALAT1 Lung cancer44,45, hepatocellular cancer46, bladder cancer47 
PCGEM1 Prostate cancer48 










GAS5 Breast cancer51 
MEG3 Pituitary adenoma52,53, meningioma54, hepatocellular cancer55, 
thyroid cancer56 
PTENP1 Prostate cancer57 
TUSC7 Colorectal cancer58 
 
MECHANISMS OF LNCRNA DEREGULATION IN CANCER 
Almost every cell in the body of a multicellular organism has the potential to 
abandon its task and develop into a tumor. Cancer cells are characterized by their 
ability to evade the intrinsic mechanisms that prevent uncontrollable growth and 
dedifferentiation59. These characteristics result from genetic changes that are either 
acquired during the lifetime of an individual (somatic) or inherited (germline). 
Somatic mutations arise from exogenous mutagenic exposures and mitotic DNA copy 
errors and accumulate over time60. While the majority of the mutations are so-called 
passenger mutations that will not confer growth advantage, some mutations will by 
chance affect one of the many cancer genes in the genome. These mutations are 
driver mutations and they promote progression of a cell into a cancer cell.61. 
Mutations can be small, affecting only a single basepair or larger such as 
translocations and copy-number variations. Somatic copy-number aberrations 
(SCNAs) are extremely common in cancer and due to their size the earliest studied 
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type of genetic change62. By studying the copy-number profile of cancer cells, 
researchers have discovered many important oncogenes and tumor suppressor 
genes. In doing so, they contributed to development of improved therapeutics and 
treatments63. While some cancer genes are rarely affected or affected only in 
specific cancer types, others are broadly affected in many patients and entities. MYC 
and CDKN2A/B for instance, exhibit copy-number chances in as many as 30% of all 
human tumors64. 
Even though SCNAs affecting protein coding genes in cancer have been extensively 
studied, lncRNAs have been largely overlooked in this regard. This can be explained 
by the use of outdated genomic annotation in the design and analysis of the used 
platforms. To overcome this problem, some researchers have repurposed existing 
DNA microarray platforms and re-annotated the probe content with current lncRNA 
annotation43,65. These efforts led to the identification of new prostate cancer 
associated lncRNAs65 and the discovery of the oncogenic lncRNA FAL1 (focally 
amplified lncRNA on chromosome 1)43. 
Single nucleotide polymorphisms (SNPs) constitute a second class of well-studied 
alterations in the cancer genome. Especially due to the many genome-wide 
association studies (GWAS), numerous SNPs have now been linked to specific 
diseases including cancer. Interestingly, about half of the cancer GWAS hits fall 
outside of known protein coding loci. While some likely affect cis-regulatory regions 
of nearby genes, many of those may be transcribed as lncRNAs66. Early evidence of 
SNPs affecting the function of lncRNAs in cancer has been reported for the lncRNA 
ANRIL67. In fact, ANRIL was identified as a major genomic hotspot in GWAS. The 126 
kb gene spans several SNPs that are associated with a variety of diseases including 
gliomas and basal cell carcinomas. More recently, re-annotation of SNP and GWAS 
databases provided many more SNPs that potentially affect lncRNAs68. To detect 
disease-causing SNPs in protein coding genes, the discrimination between 
synonymous SNPs (those that do not alter the protein sequence) and non-
synonymous SNPs is typically made. It is important to note that this classification is 
not usable for lncRNA SNPs. While some authors have tried to predict the effect of 
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SNPs on the secondary RNA structure69, the field currently lacks established tools 
that can be used for these predictions. 
Given that the mature RNA is the functional form of lncRNA genes, measurements of 
lncRNA expression therefore closely represent the levels of the active molecule. 
Quite a few lncRNAs exhibit deregulated expression in cancer that is often reported 
as predictive for disease severity and progression41,45,47,70. As such, whole-
transcriptome analysis of cancer tissue led to the identification of several 
differentially expressed lncRNAs, for instance PCAT-1 in prostate cancer71. Recently, 
analysis of the combined transcriptomes of thousands of cancer and normal samples 
revealed 8,000 lineage or cancer-associated lncRNA genes10.  
LNCRNAS TO THE CLINIC 
Although lncRNA therapeutics is still in the early stages of development, their tissue4 
and cancer10 specific expression makes them ideal candidates both as biomarkers 
and targets for therapy. In addition, lncRNAs are often found to be involved in 
epigenetic regulation of many target genes72 and, as such, can exert broad effects on 
gene expression and cell functioning.  
Obviously, targeting oncogenic lncRNAs would be an interesting therapeutic 
approach. Down-regulation of lncRNA expression in vivo can be achieved by 
antisense technology such as antisense oligonucleotides (ASOs)44. While the first 
antisense drugs showed poor performance in clinical trials73, second generation 
drugs are well on their way to the clinic with many drugs efficiently targeting both 
protein coding and non-coding RNAs74. Degradation of an oncogenic lncRNA is 
however not required to disturb its undesired activity. As many lncRNAs require 
interaction with protein partners such as Polycomb repressive complex 2 (PRC2) to 
exhibit their function, a disruption of this interaction is sufficient to block lncRNA 
functionality. Such a steric hindrance could be achieved by both small molecules and 
ASOs, the latter being currently under development by the Massachusetts-based 
company RaNA Therapeutics75.   
In particular lncRNAs that act in cis on tumor suppressor genes make interesting 
potential drug targets. As antisense lncRNAs typically repress transcription from the 
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opposite strand, targeting them could induce expression on the sense strand. 
Researchers have demonstrated this concept in vivo for the BDNF locus, as targeting 
the BDNF-AS transcript with ASOs resulted in a sevenfold increased expression of 
BDNF76. Given the frequent occurrence of antisense transcription77, this could be an 
approach to reactivate specific tumor suppressor genes in cancer. 
LncRNAs have been proposed as potent biomarkers in cancer as the expression 
levels of several lncRNAs have been shown to be indicative for disease severity or 
progression41,45,47,70. Furthermore, several lncRNAs are present in bodily fluids at 
detectable levels. For instance, the hepatocellular carcinoma associated lncRNA 
HULC (highly upregulated in liver cancer) shows great potential as biomarker since 
its expression is highly correlated with tumor grade. HULC RNA is detectable in 
plasma of patients which makes testing fast and safe70. Even more convenient 
testing is possible through exosomal lncRNA in urine. Linc-p21 for instance, has a 
higher exosomal concentration in the urine of patients with prostate cancer78. 
Although the majority of lncRNA based biomarkers are still under development, one 
lncRNA already found its way to the clinic as a biomarker in prostate cancer. The 
Progensa PCA3 assay, based on the concentration of the prostate cancer associated 
3 (PCA3) lncRNA in urine, was recently approved by the FDA as biomarker for 
prostate cancer79; urinary PCA3 levels are predictive for positive biopsies and 
outperform other biomarkers80. 
I.4. MECHANISMS OF LNCRNA FUNCTION 
LNCRNAS AS GUIDES OR SCAFFOLDS FOR CHROMATIN MODIFICATION 
Chromatin remodeling is an important mechanism for the regulation of gene 
expression at specific loci. Euchromatin is an open structure whereby the DNA is 
accessible enabling active transcription, whereas heterochromatin is more 
condensed with little or no transcription possible. The transition between the two 
states depends heavily on modifications of specific amino acids in the N-terminal 
tails of histones, often referred to as the histone code. The effect of the modification 
depends on the histone (H2A, H2B, H3 or H4), type of modification (commonly 
acetylation or methylation) and the specific amino acid that is modified, making the 
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histone code extensive and complex81,82. A feature associated with transcriptionally 
silenced chromatin is trimethylation of histone H3 on lysine 27 (H3K27me3) brought 
about by PRC2. This multiprotein complex localizes to specific sites in the genome 
where H3K27 is methylated through its enzymatic subunits EZH1 and EZH283. PRC2 
and other chromatin-modifying complexes are often ubiquitously expressed and 
target a wide range of genes, while the epigenetic pattern heavily depends on cell 
type and condition. What determines the specificity of these enzymatic complexes 
has long remained unclear, but is now thought to be mediated by specific 
lncRNAs72,83. Several lncRNAs have been found to associate with and guide PRC2, 
notable examples are XIST84, HOTAIR18 and ANRIL85. Interestingly, some lncRNAs 
target PRC2 in cis to nearby genomic loci84 while others work in trans18 on many loci 
spanning several different chromosomes. 
In addition to PRC2, lncRNAs have been found to function as a guide for other 
chromatin-modifying complexes as well. HOTTIP for instance, regulates gene 
activation by interacting with WDR5, directly recruiting the MLL H3K4 methylase 
complex to maintain H3K4me3 (H3K4 methylation is associated with active 
transcription)86. HOTAIR is an intriguing example, as this lncRNA appears to interact 
with both demethylase and methyltransferase complexes. The 5’ domain of HOTAIR 
interacts with components of PRC2 while the 3’ domain binds lysine specific 
demethylase 1A (LSD1) a component of CoREST/REST repressor complexes. LSD1 
mediates H3K4me2 demethylation. In the absence of HOTAIR, H3K4me2 gain and 
H3K27me3 loss is observed in the HOXD locus, suggesting that HOTAIR functions 
both as a molecular scaffold and as a guide of PRC2 and LSD187 (Figure 2a). 
LncRNAs with a guide function are thus believed to associate both with protein and 
DNA and function as a bridge between both. RNA-protein interactions are fairly 
common; in fact RNA-binding proteins are one of the most abundant human protein 
classes with over 1,500 members88. RNA-protein interactions require a complex 
three-dimensional structure of both the RNA and the protein and generally involve 
conformational changes to either or both interaction partners89. The exact 
mechanism of RNA-DNA interaction however, remains unclear. Local RNA:DNA 
hybrid triplexes are a possible explanation90, but there is little evidence to support a 
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widespread role for such a mechanism. Preliminary results from chromatin isolation 
by RNA Purification (ChIRP)91 have revealed that genomic lncRNA binding sites are 
small, numerous and sequence specific. As chromatin marks typically span several 
kilobases, this indicates that chromatin-modifying complexes are recruited by 
lncRNAs to specific loci and subsequently spread out bilaterally92. However, more 
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If lncRNAs can bind with proteins to enhance their function, it is not hard to imagine 
they can inhibit protein functions as well. The lncRNA GAS5 (growth arrest–specific 
5) for instance, functions as a repressor of the glucocorticoid receptor (GR) when 
cells undergo growth arrest due to starvation. A specific domain located in the stem 
of a hairpin in the mature GAS5 RNA highly resembles genomic glucocorticoid 
response elements (GRE) normally found in the regulatory regions of glucocorticoid-
responsive genes. GR recognizes and binds this domain on GAS5 and can no longer 
carry out its normal function as a transcription factor26 (Figure 2b). Other 
transcription factors are inhibited by lncRNAs as well. The transcription factor NF-YA, 
known for the induction of pro-apoptotic genes downstream of p53, is blocked by a 
lncRNA from the CDKN1A locus named PANDA (P21 associated ncRNA DNA damage 
activated)93. 
In addition to transcription factors, lncRNAs have been show to function as decoys 
for DNA methyltransferases. In this way, they can prevent gene silencing in cis as 
was shown for the CEBPA locus. Together with CEBPA mRNA, a lncRNA spanning the 
locus in sense is transcribed. This 4.5 kb RNA is termed extra-coding CEBPA 
(ecCEBPA) as it spans the entire coding region of CEBPA. It interacts with DNA 
methyltransferases 1 (DNMT1) through a stem-loop structure and protects the 
CEBPA locus from genomic methylation by the methyltransferase. This mechanism, 
whereby a sense spanning lncRNA prevents silencing of an actively transcribed locus, 
may exist for many more genes94. 
COMPETING ENDOGENOUS RNAS 
MicroRNAs (miRNAs) comprise an extensively studied class of small (21-25 nt) non-
coding RNAs. They restrain the translation of their target mRNAs typically by 
incomplete basepairing with the 3’ UTR region of the target at specific seed regions. 
The target RNA is recognized and degraded by a miRNA-loaded RISC protein 
complex, ultimately leading to a decrease in the protein abundance of the target95. 
LncRNAs can interfere with the function of miRNAs, as was first shown for the PTEN 
pseudogene PTENP1. Since the 3’ UTR of PTENP1 is highly homologous to that of 
PTEN, they share several miRNA seeds. Regulatory miRNAs that would normally 
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target PTEN bind to PTENP1 instead. PTENP1 thus acts as a miRNA decoy and 
prevents downregulation of the PTEN tumor suppressor57  (Figure 2c). LncRNAs that 
carry out this kind of post-transcriptional regulation are also referred to as 
competing endogenous RNAs (ceRNA) or miRNA sponges. Other examples of 
lncRNAs belonging to this subgroup are LNCMD196 and LINC-ROR97. 
A very peculiar subtype of lncRNA that must be mentioned here is circular RNA 
(circRNA). Members of this recently discovered class of RNA, such as ciRS-7, have 
been shown to function as highly efficient miRNA sponges due to their resistance to 
conventional miRNA destabilization98,99. 
However, these individual examples are most likely oversimplifications as crosstalk 
between different RNA species through miRNA binding sites is likely common. It is 
hypothesized that a large number of RNAs, both coding and non-coding, compete for 
the same set of miRNAs, thus forming a large-scale regulatory network100. 
LNCRNAS CONTROL TRANSCRIPTION IN CIS 
Several lncRNAs have been found to directly regulate the expression of other genes 
in the same locus101. Furthermore, a large number of lncRNAs reside in annotated 
enhancer regions102,103. An example is EVF2, a lncRNA transcribed in the enhancer 
region of DLX5 and DLX6. EVF2 combines with DLX2, a protein encoded in a different 
DLX gene cluster. Together, the EVF2-DLX2 complex promotes the transcription of 
the DLX5/6 gene cluster (Figure 2d). Using incremental deletions, the functional 
domain of EVF2 was narrowed down to a 300 bp region that corresponds to an 
ultraconserved region in the genome104. 
A different subclass of lncRNAs that regulates gene expression in cis is that of the 
natural antisense transcripts (NATs). NATs are typically defined as transcripts that 
overlap in part with a protein coding transcript but are transcribed from the 
opposite DNA strand105. For the majority of protein coding loci, antisense 
transcription is observed, making this a large but poorly understood subclass of 
lncRNAs. Although several NATs function by directing epigenetic mechanisms 
already described in previous sections, they can also reduce transcription of the 
sense strand via a mechanism determined by their orientation. The transcription 
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collision model states that the act of transcription on the antisense strand rather 
than its product inhibits transcription of the sense strand77.  It is unclear however 
how many NATs follow this model of transcriptional repression. Due to their (partial) 
sequence complementarity, NATs can form RNA duplexes with the sense transcript 
and interfere with splicing and RNA editing77. A well-studied example of this kind of 
post-transcriptional regulation is found in the ZEB2 locus. In the absence of the NAT, 
which is transcribed from a different promoter downstream of the ZEB2 promotor, 
the ZEB2 gene cannot be translated. Only when the ZEB2 NAT is expressed together 
with the ZEB2 transcript, efficient translation occurs. This particular NAT 
complements a splice site in the 5’ region of the ZEB2 transcript and induces intron 
retention upon annealing. The intron contains an internal ribosome entry site 
required for efficient translation and expression of the ZEB2 protein106 (Figure 2e).  
Although antisense transcription seems to be a prevalent feature of eukaryote 
genes, the NATs are likely a diverse group of lncRNAs that enhance or reduce 
transcription of the sense transcript.  
In addition to NATs, many transcript loci produce Promoter Upstream Transcripts 
(PROMPTs). These unstable RNA transcripts are produced up to 2.5 kilobases 
upstream of active transcription start sites. The function PROMPTs is currently 
unresolved although it is speculated that they affect nearby gene expression by 
competition for transcription machinery107,108. 
LNCRNA SUBCLASSIFICATION 
It is apparent that several lncRNAs have a function that is mechanistically dependent 
on their relative position and orientation to adjacent protein coding genes. As a 
result, this is often used to subclassify lncRNAs into distinct classes109-112. Although 
different authors have been using slightly different definitions, the following five 
classes are typically distinguished: 
Antisense. The lncRNA is transcribed from the opposite strand to the protein coding 
gene. Overlap can be complete or partial. 
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Intronic. The entire lncRNA transcribed is contained within an intron of a protein 
coding gene. Sometimes a further distinction is made according to the relative 
orientation to the protein coding gene. 
Bidirectional. The lncRNA and the protein coding gene are divergently transcribed 
with the start positions within a few hundred basepairs of each other. 
Sense overlapping. The lncRNA and protein coding gene overlap and reside on the 
same strand. As such they share a portion of their sequence. 
Intergenic. LncRNA that no dot overlap with a protein coding gene on either strand. 
I.5. LNCRNA CONSERVATION 
In the past, sequence conservation has proven to be a valuable selector for 
functionality. The low conservation of lncRNAs compared to mRNAs8,113 has thus led 
some researchers to regard them as just functionless artifacts of transcription114. 
Notably, the amount of non-coding DNA in an organism’s genome is highly 
correlated with biological complexity115. As such, one could argue that the 
differences found in protein coding genes alone cannot explain the distinction 
between higher evolved species and more primitive ones, and that recently evolved 
evolutionary adaptations can only be explained by recently evolved genetic entities 
found in the non-coding part of the genome. In addition, basepair conservation 
scores such as PhastCons116 or PhyloP117 might not be suitable measures to assess 
the true functional conservation of a non-coding gene. For instance, although the 
function of XIST is conserved between human and mouse, its sequence shows poor 
overall conservation118. The position of the XIST-specific tandem repeats (key 
elements in the function of XIST) however showed striking resemblance between the 
two species. This suggests that not the sequence but the position and pattern of 
tandem repeats is responsible for the functional conservation of the gene118. In 
addition, a large-scale study on zebrafish lncRNAs showed that for the majority of 
zebrafish lncRNAs, sequence similarity to mammalian lncRNAs is absent or limited to 
a short region of high conservation. However, in two lncRNA knockout models, the 
phenotype could be rescued by adding the mouse or human ortholog21. This 
demonstrates again that functional conservation of lncRNAs not necessarily requires 
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sequence conservation. As a result, other measures for conservation have been 
developed and used to study lncRNA evolution. When examining the conservation of 
splice sites, it was found that more than 70% of the human lncRNAs is conserved 
within placental mammals and 15% dates back even further119 (Figure 3 left panel). 
The conservation of lncRNA promoter sequences has been studied as well, and 
evolutionary selection to an extent comparable to that of protein coding genes could 
be detected for the majority of lncRNA promoters120. Of particular interest in this 
regard is a large-scale RNA sequencing effort to explore the evolution of lncRNAs 
based on their transcripts121. In this study, the transcriptomes of 8 organs from 11 
tetrapod species (ranging from Xenopus to human) were sequenced. With only a 
limited number of species-specific lncRNAs, over 80% was found to be primate-
specific (Figure 3 right panel). Although the number is relatively small, 425 lncRNAs 
(3%) appear to have originated more than 300 million year ago. Interestingly, these 
ancient lncRNAs have promoters enriched with homeobox transcription factor 
binding sites, suggesting a role in embryogenesis. Although the different methods 
used to assess lncRNA conservation each have their differences and particularities, 
they all agree that the great majority of lncRNAs is conserved to a larger extent than 




Figure 3: Two different methods shed different lights on lncRNA evolution. Splice-
site conservation (left panel) suggests that most lncRNAs were already present at the 
divergence of placental mammals (orange). Of the 5,413 human lncRNAs examined 
in this study, 2,905 (54%) have emerged at this divergence and a substantial number 
are even older. Transcript sequence similarity (right panel) however, suggests most 
lncRNAs are more recent evolutionary adaptations. Here, only 1,476 (10%) lncRNA 
families are found to be specific for placental mammals while 9,584 (65%) are 
primate-specific. Even though the methods disagree on the evolutionary age of 
lncRNAs, they both yield a large number of conserved lncRNAs. Adapted from 
Nitsche et al.119 and Necsulea et al.121. 
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I.6. STUDYING LNCRNA STRUCTURE 
It is often speculated that lncRNAs perform their function through a specific and 
complex secondary and tertiary structure. Unfortunately, lncRNA structure and its 
relation to function is currently poorly understood and functional reports are mostly 
limited to small domains of the lncRNA. For instance, the tandem repeat regions in 
XIST are not only the most conserved part of the gene; they have also been shown to 
form an intricate stem-loop structure122. Components of PRC2 can specifically 
interact with this structure, suggesting that this domain functions in PRC2 
recruitment. The most conserved part of MALAT1 corresponds to a cloverleaf-like 
structure at the 3’ end of the transcript. Further processing of the transcript results 
in cleavage, producing a small tRNA-like RNA called the mascRNA (MALAT1 
associated small cytoplasmic RNA). The function of mascRNA however remains 
unclear123. 
Secondary RNA structures can be studied using either in silico or in vitro 
methodologies. Several algorithms have been implemented to predict the most 
probable conformation of nucleic acids in the cellular environment. A popular 
approach is the use of dynamic programming to find the set of base pairings that 
result in the structure with the lowest free energy. Quite a few programs are 
implementations of such an algorithm, including UNAFold124, RNAstructure125 and 
the ViennaRNA suite126. It is important to note that these algorithms are prone to 
false positives on long (> 200nt) RNA sequences and such MFE structures are 
unreliable. Therefore, it is recommended to use a sliding window approach and 
focus on local structures127. In vitro approaches are primarily based on determining 
the positional susceptibility to certain chemical modifications or nucleases. For 
instance in Selective 2’-Hydroxyl Acylation analyzed by Primer Extension (SHAPE) 128, 
the 2’-hydroxyl group the RNA ribose component is chemically modified. Single 
stranded regions, loops ore bulges are more sensitive to this reaction. To analyze 
RNA structures transcriptome-wide, SHAPE can be followed by deep RNA 
sequencing. This recently developed approach is referred to as SHAPE-Seq129. 
Similarly, Parallel Analysis of RNA Structure (PARS) is based on deep RNA sequencing 
of nuclease treated RNA. Two different nucleases are employed: the RNase V1, 
INTRODUCTION 26 
which specifically targets single stranded RNA and the S1 nuclease, which cleaves 
double stranded RNA130. 
I.7. LNCRNA CODING POTENTIAL 
Although a task of discriminating protein coding from non-coding RNA seems trivial, 
it has proven to be a topic of much debate. 
IN SILICO PREDICTION OF CODING ORFS 
A plethora of computational methods that aim to distinguish protein coding from 
non-coding sequences have been developed. Each method investigates features in 
the sequence or evolution of coding ORFs that set them apart from non-coding 
sequences to score transcripts of unknown coding potential. Often, some form of 
machine learning is involved in the feature selection and scoring. Notable examples 
are CPC131, CONC132, PORTRAIT133, CPAT134, PLEK135, iSeeRNA136 and PhyloCSF137. 
There is a striking similarity in the feature sets these algorithms use. Without 
assessing and comparing every algorithm in detail, a selection of interesting features 
is explored in the following paragraphs. 
By chance, a random progression of nucleotides can contain a short canonical ORF, 
but long ORFs are unlikely to be incidental. Indeed, the (relative) ORF size is often 
found to be the most powerful individual discriminator on typically used 
benchmarking sets132,136. However, one might wonder if this is not just reflecting a 
bias in current annotation. This is a plausible explanation as research and annotation 
groups have been focusing primarily on transcripts containing ORFs larger than 300 
nucleotides (100 amino acids)138. Currently, proteomics groups are shifting their 
focus to small (less than 100 amino acids) but functional proteins, often called 
micropeptides139. Although further research on this topic is needed, it is not 
unthinkable that algorithms using current annotation as training or benchmarking 
data and ORF size as a scoring feature will generate false negatives and are 
unsuitable for detecting novel micropeptides in unannotated transcripts. 
A second feature used by several coding potential prediction programs is similarity 
to annotated protein sequences131,132. Bioinformatics tool such as BLASTX allow 
efficient querying of protein databases using nucleotide input sequences140. The ORF 
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sequence can thus be used and the number of hits and the corresponding scores can 
serve as training parameters for the prediction model131,132.  A high homology to the 
sequences of known proteins may however be unsuitable to detect coding ORFs in 
novel transcripts. ORFs encoding proteins that are biologically distinct from already 
reported proteins, such as ORFs of micropeptides, will likely be classified as non-
coding. In addition, since most annotated protein coding genes are represented in 
protein databases as well, typically used benchmarking datasets will result in an 
overestimation of the sensitivity obtained from this feature. 
Although coding and non-coding RNA share the same alphabet, they speak a 
different language. The nucleotide composition of putative coding ORFs is thus 
expected to differ from that of ORFs arisen by random variation. In addition to single 
nucleotide distributions, k-mer distributions (with k ranging from 1 to 6) have been 
proven to be informative as well134,135. Trimer distributions are especially important 
as those reflect the codon usage within the ORF. While several different codons can 
be translated to the same amino acid, some codons seem preferred over others. This 
codon usage bias is one of the oldest described features of coding sequences141. 
Overall, the nucleotide composition entails a powerful set of features based on 
intrinsic properties of coding ORFs with little bias to current annotations. 
Over the course of evolution, synonymous nucleotide substitutions are more 
common since they do not alter the function of the protein. This evolutionary 
pattern can be observed in the codon substitution frequencies across multispecies 
whole genome alignments. The phyloCSF algorithm137 makes use of these codon 
substitution frequencies to estimate the likelihood that a given ORF represents a 
conserved coding sequence. PhyloCSF was able to detect novel proteins in many use 
cases and it has proven to be applicable even for the detection of small proteins 
including micropeptides142. 
In conclusion, a wide selection of programs or methods to assess coding potential in 
unannotated transcripts is available. The performance of several programs is 
excellent, with sensitivities and specificities well exceeding 95% on the used training 
and test data134. However, training data are based on the current annotation of 
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protein coding genes, which shows a strong bias toward proteins larger than 100 
amino acids143 with high evolutionary conservation. Even though it is uncertain how 
many short or evolutionary recent proteins remain to be discovered, current coding 
potential prediction methods are perhaps not the most suitable means to answer 
this question. As a result, in silico predictions show very little coding potential in 
present-day lncRNA annotations. 
RIBOSOME PROFILING: RIBOSOME OCCUPANCY AS AN INDICATOR FOR TRANSLATION 
Advances in next-generation sequencing allowed the development of numerous 
methods to study specific entities in the genome and transcriptome144. Ribosome 
profiling (also known as ribosome footprinting or Ribo-Seq) is one of those methods 
and has gained much attention in recent years. Here, enzymatic degradation of RNA 
not associated with ribosomes, followed by deep sequencing of the 28-30 nucleotide 
ribosome protected fragments is used to map ribosome occupancy to single basepair 
resolution145. Ribosome profiling experiments revealed significant ribosome 
occupancy on non-AUG ORFs, upstream ORFs (uORFs) and lncRNAs146. These 
findings, although controversial, have a great impact on our current understanding 
of translation and on the numbers of protein coding genes (and therefore also 
lncRNA genes) in the genome. The discovery of ribosome occupancy on the majority 
of lncRNA transcripts147 has been a topic of much debate in recent years. Different 
research groups have come to conflicting, even opposite conclusions on the number 
of true non-coding lncRNAs. To separate coding from non-coding ORFs using 
ribosome profiling data, several authors have developed metrics based on specific 
properties of translated RNA (Table 2). Although all of these methods acknowledge 
the existence of coding ORFs in genes currently annotated as lncRNA, most authors 
agree that the number of misclassified lncRNAs is low. Some authors however, 
remain convinced that ribosome occupancy indicates that the majority of lncRNAs is 
translated and as such are protein coding genes148. 
Besides the discussion on the interpretation of ribosome footprints from lncRNA 
transcripts, one may also pose questions on the usefulness of ribosome profiling for 
the discovery of new and functional proteins. For instance, uORFs have been 
recognized as regulatory elements for several years. Although they function by 
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association with ribosomes, they probably do not encode functional proteins149,150. 
The finding that the ribosome footprints of lncRNA ORFs resemble those of uORFs 
more than those of coding ORFs (Figure 4) further supports the hypothesis that the 
ribosome footprints on lncRNA ORFs resemble regulatory rather than coding 
events151. Regulatory ORFs on lncRNAs may for instance control the steady state152 
or subcellular localization153 of the transcript. 
Despite the recent advances in ribosome profiling analysis, the debate on the role of 
lncRNA ORFs will probably last until functional studies show that such ORFs are 
nonessential for the function of the lncRNA or that proteomics shows that they 
encode functional and stable peptides.  
 
Figure 4: Although ribosome occupancy is found on both coding and non-coding 
ORFs, several metrics can clearly distinguish these profiles. Coding ORFs have lower 
ribosome occupancy after the stop codon, resulting in a higher ribosome release 
score (RSS) compared to ORFs in the UTRs. Furthermore, 3’ ORFs exhibit a lower 
translation efficiency (TE). Adapted from Chew et al.151 
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Table 2: Overview of metrics and methods used by different authors to distinguish coding and non-coding ORFs based on ribosome profiling. 
Different authors draw contrasting conclusions from the ribosome occupancy observed on lncRNA. While some report evidence for translation 
for the great majority of lncRNAs, others find only small numbers of true translation events. 
Metric Publication Definition Conclusions 
Translational 
efficiency (TE) 
Ingolia et al., 2011147 
Ruiz-Orera et al,., 2014154 Ratio of number of ribosome protected reads and RNA-seq reads for an ORF. The majority of lncRNAs contain regions of high translation comparable to 
protein coding genes. 
Translation initiation 
sites (TIS) 
Lee et al., 2012155 Lactimidomycin was used to specifically stall 
initiating ribosomes. A TIS is a position in 
which initiating ribosomes are enriched 
above a measured background. 
A limited number (4%) of the analyzed 




Guttman et al., 2013156 Ratio between the normalized number of 
reads that are contained within the putative 
ORF and the normalized number of reads 
contained within the putative 3’ UTR. 




Chew et al., 2013151 Random forest classifier combining TE, RRS, 
the ratio of bases covered within an ORF 
Less than 10% of mouse lncRNA loci are 
classified as coding. Interestingly, most 
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versus outside and the relative ORF size. 
Trained on annotated protein coding genes 
and classifies ORFs as coding, leader-like and 
trailer-like.  
lncRNA ORFs resemble upstream ORFs 
of coding genes. 
ORFscore Bazzini et al., 2014157 The periodicity of ribosome movement is 
detectable in ribosome profiling data. The 
proportion of codons with in-frame reads is 
here compared to a uniform distribution 
using a modified chi-squared statistic. 
Less then 1% of the analyzed lncRNA 




Ingolia et al., 2014148 Measures the disagreement between the 
observed and expected fragment length 
distribution. 
The vast majority of lncRNAs (90%) 





MASS SPECTROMETRY: SEE IT TO BELIEVE IT 
Shotgun proteomics is the method of choice for high throughput analysis of proteins 
in complex mixtures by identification of individual peptides. In this approach, 
proteins are first enzymatically digested, producing complex mixtures of peptides. 
Next, peptides are separated often using liquid chromatography (LC). Typically, 
individual peptides are ionized and then analyzed in a two-step process called 
tandem mass spectrometry (MS/MS). First, the mass-to-charge ratio (m/z) of the 
entire peptide ion is measured followed by fragmentation of this peptide ion and 
acquisition of an m/z spectrum of its fragment ions (MS/MS spectrum). In this way a 
MS/MS spectrum is obtained for every peptide158,159. From this spectrum the 
peptide’s amino acid composition can be read using computational methods. 
Commonly, a database search method is used whereby MS/MS spectra are 
compared to theoretical spectra generated from known protein sequences158. To 
use this approach for the discovery of novel proteins, protein sequence databases 
must be extended with predicted protein sequences. In addition, computationally 
intensive de novo sequencing can predict the sequence from an MS/MS spectrum158. 
Several research groups have turned to shotgun proteomics to evaluate putative 
ORFs on lncRNAs. Therefore, predicted ORFs based on transcriptomes or genome 
sequences are added to the protein search space. The first such effort, termed 
Pinstripe, employed non-redundant peptides from the public PRoteomics 
Identifications DatabasE (PRIDE). The peptide sequences were mapped to a custom 
transcriptome based on RNA sequencing of 16 human tissues. From this 
transcriptome the authors reported 736 canonical open reading frames (ORFs) 
supported by three or more PRIDE peptides compared to over 32,000 non-coding 
loci160. A significant fraction, although the authors admit their method is likely to 
generate considerable number of false positives. Indeed, more extensive approaches 
using (re)processing of MS/MS spectra have come up with much smaller numbers. 
Slavoff et al. combined proteomic and transcriptomic analysis of the K562 human 
leukemia (CML) cell line. Their database consisted of RefSeq mRNA transcripts and 
three-frame translated transcripts obtained from RNA sequencing. By analyzing 
MS/MS spectra against this database they identified 90 micropeptides, 8 of which 
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are encoded by lncRNAs. These 8 micropeptides represent just 0.4% of the 1,866 
lncRNA transcripts detected using RNA sequencing161. Similar approaches that 
instead made use of ribosome profiling to define the in silico peptidome have been 
developed as well162-164. In mouse and human cell lines these approaches came up 
with respectively 83 and 22 novel micropeptides.  
Overall, the numbers of (small) proteins encoded by lncRNAs that are detected by 
mass spectrometry appear to be rather limited and not in line with the high numbers 
suggested by some ribosome profiling studies. Several explanations for this 
discrepancy are possible. First of all, ribosome occupancy alone may not be a good 
indicator for active translation, as was already indicated by specific ribosome 
profiling efforts156. Secondly, it is possible that the translation events produce 
unstable proteins that are readily degraded and as such undetectable by proteomics. 
In addition, it is possible that the translation events are rare and generate only low 
amounts of protein that are difficult to detect using proteomics.  
It is apparent that the discrimination between coding and non-coding RNA is far 
from trivial. Even though the advent of ribosome profiling promised better insight in 
the translation of the transcriptome it leaves much room for interpretation. The 
finding that ribosome occupancy on lncRNAs more closely resembles that of non-
coding ORFs in mRNA UTRs along with the low numbers of detected proteins by 
means of proteomics points to a true non-coding role for lncRNAs. 
I.8. LNCRNA ANNOTATION IN REFERENCE DATABASES 
As lncRNA is currently well accepted as a genetic subclass by the genetic research 
community, lncRNA annotations are slowly finding their way to the international 
reference databases. These curated annotations represent a more established 
subset of lncRNAs based on several lines of evidence. Both the European Ensembl165 
initiative and their American counterpart RefSeq166 make use of a combination of 
automated annotation pipelines and manual curation. RefSeq classifies RNA 
sequences as either coding (NM_* records) or non-coding (NR_*) records. Therefore, 
the non-coding records are not limited to lncRNAs but include non-coding transcripts 
such as transcribed pseudogenes or non-coding isoforms of protein-coding genes. 
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Ensembl makes use of a more elaborate classification schema consisting of many 
biotypes. Interestingly, lncRNAs are subclassified in 11 distinct biotypes including 
lincRNA (long interspersed non-coding RNA)167. 
I.9. CONCLUSION 
Although the first lncRNA was discovered in 1990168, it took several decades for 
geneticists to grasp the true scale of this genetic class. Recent advancements in next-
generation sequencing technology uncovered tens of thousands of lncRNA loci in the 
human genome. Even though the great majority remains to be functionally studied, 
some common themes seem to be emerging. 
By an assortment of molecular mechanisms, lncRNAs can affect gene expression 
both in cis and in trans. As such, they are involved in many cellular processes and 
play a role in different genetic diseases. Our current understanding of lncRNA 
evolution and conservation is poor and restricted to preliminary research that looks 
beyond sequence conservation to identify lncRNA orthologs. Similarly, the 
assessment of lncRNA coding potential remains elusive, with conflicting reports 
coming from authors using slightly different analysis methods. All in all, lncRNAs 
have proven to be a class of genes with intriguing features. Nevertheless many 
secrets remain that will likely continue to unfold over the next few years. 
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II. RESEARCH OBJECTIVES 
Even though the lncRNA research field is still young, it is growing at an immense 
pace. An ever-increasing number of lncRNAs is being reported in literature as the 
number of research labs that shift their focus to lncRNA grows. The rapidly changing 
lncRNA annotations in numerous lncRNA resources however, are a burden to the 
field as this diversification impedes scientific communication. The established 
genetic databases struggle to keep up with lncRNA literature or take a conservative 
position and await further research. As both bioinformatics and wet-lab applications 
rely on lncRNA annotation, lncRNA researchers find it difficult to use the currently 
available platforms. To address this issue, we developed LNCipedia, a public lncRNA 
resource that aims to provide the most complete and up-to-date view on the 
lncRNome (research paper 1). In order to fulfill this promise, LNCipedia has been 
updated on several occasions and currently holds over five times the initial number 
of entries (research paper 2). Without functional validation, it is not straightforward 
to distinguish between coding and non-coding RNA, as was already thoroughly 
discussed in the introduction. To address this issue, we have evaluated several 
methods to assess the coding potential of lncRNA transcripts. In collaboration with 
the research lab of Prof. Martens, we devised a strategy to query large-scale 
proteomics datasets for putative protein products of lncRNAs. While we already 
introduced this method in the LNCipedia publications, we aim to publish a 
commentary paper as well, in which we comment on the discrepancy observed 
between our results and some ribosome profiling studies (research paper 3).  
With a lncRNA database at hand, we were able to develop a number of platforms to 
functionally study lncRNAs in screening experiments. Gene expression microarrays 
are often the method of choice for high throughput expression profiling 
experiments. As commercial platforms typically lack extensive lncRNA annotation we 
developed and subsequently updated a custom gene expression microarray covering 
both protein coding and lncRNA transcripts (case study 1). In addition, we designed a 
unique platform to detect small and focal copy-number aberrations targeting lncRNA 
genes. Since oncogenes and tumor suppressor genes are frequent targets of genetic 
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amplifications or deletions respectively, we reasoned that screening the cancer 
genome for genetic aberrations on lncRNAs is a valuable method to identify novel 
cancer associated lncRNAs. As such, we screened a panel of 80 cancer cell lines using 
our platform and found many putative cancer associated lncRNAs (research paper 
4). The ability to transiently impede gene expression in vitro is invaluable for 
functional genomic research. While for protein coding genes this can easily be 
achieved by various means, their lower expression and nuclear localization make 
lncRNA harder to target. We evaluated the potential of ASOs for lncRNA knockdown. 
In addition, we developed a tool to assess the potential of an ASO using its 
thermodynamic properties and target RNA structure (research paper 5). 
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ABSTRACT
Here, we present LNCipedia (http://www.lncipedia
.org), a novel database for human long non-coding
RNA (lncRNA) transcripts and genes. LncRNAs con-
stitute a large and diverse class of non-coding
RNA genes. Although several lncRNAs have been
functionally annotated, the majority remains to be
characterized. Different high-throughput methods
to identify new lncRNAs (including RNA sequencing
and annotation of chromatin-state maps) have been
applied in various studies resulting in multiple unre-
lated lncRNA data sets. LNCipedia offers 21 488
annotated human lncRNA transcripts obtained
from different sources. In addition to basic tran-
script information and gene structure, several stat-
istics are determined for each entry in the database,
such as secondary structure information, protein
coding potential and microRNA binding sites. Our
analyses suggest that, much like microRNAs,
many lncRNAs have a significant secondary struc-
ture, in-line with their presumed association with
proteins or protein complexes. Available literature
on specific lncRNAs is linked, and users or authors
can submit articles through a web interface. Protein
coding potential is assessed by two different predic-
tion algorithms: Coding Potential Calculator and
HMMER. In addition, a novel strategy has been
integrated for detecting potentially coding lncRNAs
by automatically re-analysing the large body of
publicly available mass spectrometry data in the
PRIDE database. LNCipedia is publicly available
and allows users to query and download lncRNA se-
quences and structures based on different search
criteria. The database may serve as a resource to
initiate small- and large-scale lncRNA studies. As
an example, the LNCipedia content was used to
develop a custom microarray for expression
profiling of all available lncRNAs.
INTRODUCTION
Long non-coding RNAs (lncRNAs) constitute a recently
discovered class of non-coding RNAs that grew in size
drastically during the past few years. LncRNA genes
give rise to long (>200 bp) and often multiexonic tran-
scripts that are supposed not to get translated to
protein, as commonly assessed by means of in silico pre-
diction algorithms (1). In comparison with their
protein-coding counterparts, lncRNA genes are poorly
conserved (2) and are more numerous in biologically
complex species (3). Although only a fraction of the
lncRNA genes has been characterized experimentally,
lncRNAs seem to function as transcriptional regulators
through direct interaction with chromatin-modifying
proteins and transcription factors (1,4,5).
LncRNAs with experimentally validated functions or
expression patterns have been named accordingly.
Notable examples are XIST (X inactive-specific transcript)
(6), HOTAIR (HOX transcript antisense RNA) (7) and
HULC (highly up-regulated in liver cancer) (8). The
HUGO Gene Nomenclature Committee currently uses
several schemes to name lncRNAs with an unknown
function. LncRNAs that reside on the opposite strand to
(antisense) or in an intron of (intronic) a protein-coding
gene are named after the protein-coding gene with suffixes
‘-AS’ and ‘-IT’, respectively. Intergenic lncRNAs are
numbered and get the prefix ‘LINC’ (9).
Recent advances in non-coding RNA research have led
to the creation of several lncRNA resources. LncRNAdb
focuses on lncRNA transcripts with well-described func-
tions in literature (10), whereas the ncRNA database
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(ncRNAdb) provides RNA sequences and annotation
from different sources (11). The NONCODE database
(12) contains a larger collection of human long
non-coding RNAs (33 829) obtained from different
sources and by different experimental procedures (13).
Rfam provides structures and annotation of well-known
RNA families along with predictions of new members of
these families (14). However, it does not provide informa-
tion for an individual lncRNA. Although each of these
resources provides valuable information, database unifica-
tion and integration of lncRNA transcript sequence
details with a broad set of bioinformatics tools and a uni-
versal lncRNA gene building and naming scheme is cur-
rently lacking. Here, we present LNCipedia, a catalogue
of 21 488 lncRNA transcripts that were clustered into
genes and named accordingly, and they were analysed
using multiple bioinformatics tools, revealing insights in
lncRNA structure, experimentally verified (lack of)
protein coding potential, function and regulation. We
believe such a database facilitates human lncRNA
research and communication among scientists.
DATABASE DEVELOPMENT
The sources used in the data collection step are listed in
Table 1. The most recent version of each source at the time
of development has been included. The sequences and
annotations are extracted and stored in a mongoDB
database using custom Perl scripts. To this purpose,
import scripts for different file formats, such as FASTA,
BED and GFF, have been developed. Redundant tran-
scripts are grouped in a single record, while maintaining
all annotation from the original sources. The web interface
for LNCipedia is build using the Mojolicious Perl web
framework and offers different ways of querying the
data (Figure 1). LNCipedia will be updated when newer
versions of the lncRNA sources are released or if new
sources become available. In addition, researchers are
encouraged to submit new transcript sequences or anno-
tations trough lncipedia.org.
Of note, each of the input sources uses a different
naming scheme. LncRNA researchers have previously
used the gene symbol of the nearest protein coding
gene to refer to a given lncRNA (15). Based on this
strategy, we have implemented a universal lncRNA no-
menclature to ease communication among researchers.
Different lncRNA transcripts are considered to belong
to the same gene if they share at least one (partially)
overlapping exon and reside on the same DNA strand.
In this way, transcripts are clustered into genes. These
lncRNA genes are then named after the HUGO symbol
of the nearest protein-coding gene on the same strand
using the following scheme: ‘lnc-HUGO-#’. The
lncRNA genes are numbered, starting with the lncRNA
gene closest to the protein-coding gene. A second
number is added to denote the different transcript
variants starting with the most upstream transcript, for
example, lnc-MYCN-1:1 denotes transcript 1 from gene
lnc-MYCN-1 (Figure 2).
INTEGRATED ANALYSIS TOOLS
LncRNA-protein interactions are, in part, mediated by
the secondary structure of the lncRNA. The Vienna
RNA package (16,17) consists of a set of algorithms for
predicting and analysing RNA secondary structures. We
applied the RNAfold algorithm to generate a secondary
structure plot and dot plot with pair probabilities. Both of
these images are processed with the provided relplot.pl
script to obtain a structure plot with colour annotated
base pair probabilities. The output postscript (.ps)
images are converted to the graphics interchange format
(.gif) for display in web browsers.
Structural RNAs, such as miRNAs, have a significantly
lower minimum free energy of folding compared with
randomly shuffled sequences (18). The Randfold algo-
rithm implements the randomization test and returns the
mean free energy of folding and P-value for every RNA
sequence. Hence, a significant P-value denotes a high pro-
pensity in the sequence towards a stable secondary
structure.
Recently, it has been shown that lncRNAs can act as
a miRNA sponge by binding specific microRNAs and,
thus, interfering with their role as negative regulators of
gene expression (5,19,20). We include miRNA seed pre-
dictions for every lncRNA to allow researchers to evaluate
possible miRNA–lncRNA interactions. miRNA seed
predictions were performed using the MirTarget2
algoritm (21).
PROTEIN CODING POTENTIAL
Assessment of protein coding potential is an important
aspect in the study of non-coding RNAs. LNCipedia
reports the outcome of two different protein coding
potential prediction algorithms. The Coding Potential
Calculator (CPC) applies a support vector machine
classifier to the output of open reading frame analysis
and Basic Local Alignment Search Tool search (22).
CPC returns the predicted status of the transcript
(coding/non-coding) and a coding potential score. We
applied version 0.9 of the CPC software and report the
predicted status and the coding potential score for every
transcript. Another popular strategy for detection of
Table 1. The different sources of lncRNA transcripts used for
LNCipedia at the time of developmenta












aThe database will be updated with new transcripts when new versions
of the sources are released.
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coding sequences is based on known protein domains. The
HMMER3 suite provides software based on hidden
Markov models for sequence based homology searches
(23). It is often used in combination with the Pfam
protein families database (24). Using the hmmscan
algorithm, we searched for Pfam protein domains in the
RNA sequence. All six reading frames were translated in
silico, and the number of hits in 50 to 30 and 30 to 50
direction are reported.
A unique feature of LNCipedia is the incorporation of
an automated reprocessing pipeline that relies on publicly
available fragmentation spectra from the PRIDE database
at EMBL-EBI (25) to detect potentially coding lncRNAs.
The concept behind this feature is that mass spectrometry
based proteomics data may contain serendipitously
recorded mass spectra derived from translated lncRNAs.
As standard identification strategies in proteomics are
based on searching these spectra against protein
sequence databases, such as UniProtKB/Swiss-Prot (26),
they are implicitly unable to detect coding forms of
lncRNAs, as they are not present in these databases. To
uncover such potential traces of coding lncRNAs, the
spectra, thus, need to be re-searched against a purpose-
built database that comprises a combination of the
possible translations of known lncRNAs, the known
proteins for that organism as obtained from a traditional
sequence database and corresponding decoy sequences for
both these constituent databases for quality control and
FDR estimation purposes (27). A spectrum can, thus, be
matched against a lncRNA, a known protein, or a decoy
sequence. The known proteins must be included to prevent
relatively low-scoring matches of spectra against lncRNAs
to be picked up where a much better match for that
spectrum can be found for a known protein.
We have implemented such a pipeline by using the
SearchGUI tool (28) to run the X!Tandem (29) search
algorithm. All results are then collated and filtered at
1% FDR by the PeptideShaker algorithm (http://code
.google.com/p/peptide-shaker). The pipeline infers the
original search parameters, such as mass errors and
post-translational modifications both directly from the
PRIDE database and by using the PRIDE automatic
spectrum annotation pipeline (http://code.google.com/p/
pride-asa-pipeline). All the tools and algorithms used are
freely available as open source.
The pipeline has so far been ran on 149 PRIDE
experiments from at least 15 different tissues, yielding




















Figure 1. LNCipedia is generated in a multistep process that comprises importing, naming, analysis and visualization of lncRNA genes. Import
scripts for the FASTA, BED and GFF file formats process lncRNA transcripts and detect redundancy. LncRNA naming is preceded by the creation
of lncRNA transcript clusters and requires information on the nearest protein-coding gene on the same DNA strand. Every lncRNA transcript is
subsequently analysed using multiple algorithms, and the results are appended to the database. A web-interface build using Perl enables lncRNA
visualization and database querying.
Figure 2. The SOX1 protein-coding gene locus contains three lncRNAs on the same DNA strand, numbered according to their distance in relation
to SOX1. LncRNA transcripts are numbered according to their order in the gene, starting with the most upstream transcript.
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Figure 3. The transcript page in the web interface provides a clear overview of information available on a specific lncRNA transcript.
Nucleic Acids Research, 2013, Vol. 41, Database issue D249




custom-built protein sequence database that includes
UniprotKB/Swiss-Prot and LNCipedia translations
(Supplementary Figure S1). Within these PSMs, there
were just 14 matches that could provide evidence for
translation of LNCipedia entries. However, after close
inspection of the FDR of the PSMs that passed our
quality criteria, we noticed that although the PSMs from
UniProtKB/Swiss-Prot have an expected FDR of 0.9%,
the subset of PSMs from translated LNCipedia entries
comes with an overwhelming FDR of 166%
(Supplementary Figure S2). As such, there are only
vague suggestions so far that any of these entries can
effectively be translated.
As the PRIDE database is growing exponentially, and
additional lncRNA transcript discovery is ongoing,
searches for potentially coding lncRNAs need to be
carried out anew at regular intervals to stay up-to-date
with the growing amount of public data. We, therefore,
envision running the full pipeline on all applicable PRIDE
data at a set interval of 3 months; thus, periodically
updating the knowledge on which lncRNAs might have
coding potential. The output of each reprocessing effort
will be used to annotate the LNCipedia, and past results
will be kept available as well.
Besides this recurrent re-analysis of the relevant publicly
available proteomics data, we also plan to extend the
statistical approach used to evaluate the identification of
a lncRNA by including information about the consistency
with which such an identification is found across
(unrelated) PRIDE experiments. Indeed, a relatively
poor match in any individual experimental data set that,
however, keeps returning across many such data sets, may
well be a real indication that translation is taken place for
that lncRNA.
LNCIPEDIA ACCES
LNCipedia is publicly available through a web interface at
http://www.lncipedia.org. The interface allows users to
query lncRNAs by name, chromosomal region or
(partial) sequence. Several statistics are calculated that
allow the user to evaluate different parameters regarding
lncRNA secondary structure and regulation (Figure 3).
The entire LNCipedia collection is available for
download in the FASTA, GFF or BED format.
LncRNA researchers can contribute to LNCipedia by
contacting the authors. In addition, registered users can
modify existing records (updating aliases and adding
PubMed literature records) directly using a web interface.
LNCRNA EXPRESSION ARRAY
The LNCipedia content can prove useful when designing
large-scale screening experiments, such as lncRNA gene
expression profiling. As a proof of concept, we have
developed a custom lncRNA gene expression array using
the Agilent Sureprint 60 k platform. In addition to
roughly 33 000 probes for protein coding genes, we
selected 23 042 probes for lncRNA transcripts in
LNCipedia covering 97% of all LNCipedia transcripts
with at least one probe (Agilent MicroArray Design ID:
039714). The performance of the expression array was
evaluated using RNA sample titrations according to the
MicroArray Quality Control standards (30). Adequate
titration response of the lncRNA probes is shown in
Supplementary Figure S3.
CONCLUSION AND FUTURE DIRECTION
Three important features are unique to LNCipedia: gene
definitions and usage of a universal nomenclature for
lncRNA transcripts, PRIDE analysis for detection of
lncRNAs that may code for small peptides and miRNA
seed predictions for lncRNA transcripts. These, along with
the other tools available, are expected to make LNCipedia
a powerful resource for human lncRNA research.
With the advances in RNA sequencing technology,
more lncRNA genes are expected to get discovered. The
authors will update LNCipedia when new sequences are
reported in the literature or in other sources. In addition,
new features will be developed to increase the interactive
capabilities of LNCipedia. In this way, the lncRNA
community will be able to upload and maintain records
in the database. LNCipedia has the potential to become a
community resource for lncRNA transcript information
and annotation.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures 1–3 and Supplementary Methods.
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Supplemental Figure 1. Scatterplot of re-analysis of 149 PRIDE experiments. The X-axis and 
the Y-axis show the number of peptide-to-spectrum matches (PSMs) per experiment by our 
automated re-analysis and as deposited in PRIDE, respectively. For most experiments, our 
analysis yields roughly half the amount of PSMs annotated in PRIDE. One reason for this is 
that our approach applies a stringent 1% FDR cutoff, while such stringency is not required 
when depositing an experiment into PRIDE. Furthermore, our protein sequence database is 
considerably larger than UniProtKB/Swiss-Prot since it contains a translated version of 



































Supplemental Figure 2. PSM counts after re-analysis of 149 PRIDE experiments with an FDR 
limit of 1%. PSMs from UniProtKB/Swiss-Prot are called ‘false’ (left bar chart) and from 
lncRNA translations are dubbed ‘true’ (right bar chart). Decoy hits, indicative of the amount of 
false positives, are given in red, while normal hits are given in green. Note that while the left 
bar chart with UniprotKB/Swiss-Prot hits shows an expected FDR of 1%, the right bar chart 





















PSM count from PRIDE re-analyses
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Supplemental Figure 3. MAQC titration response of lncRNA probes. LncRNA expression was 
measured for samples A (Universal human reference RNA, Agilent Technologies), B (Human 
brain total RNA, Ambion), C (25% A + 75% B) and D (75% A + 25% B). The percentage of 
lncRNA probes that follow the monotonic titration response (Y-axis) is plotted in function of 
the binned log2-fold change (X-axis) between samples A and B. Titration response was 
calculated according to Shippy et al., Nature Biotechnology, 2006. 
  




















Data is read from the PRIDE database after filtering applicable experiments by taxonomy, 
number of spectra and consistent taxonomic origin of the reported proteins. The data is then 
analyzed to detect applicable search engine settings, notably the precursor and fragment ion 
mass tolerances as well as the (variable) modifications to consider. Allowed missed 
cleavages are set to 1. PeptideShaker is run in automatic mode to filter the proposed peptide-
to-spectrum matches hits at the 1% false discovery rate as calculated through the decoy 
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ABSTRACT
The human genome is pervasively transcribed, pro-
ducing thousands of non-coding RNA transcripts.
The majority of these transcripts are long non-coding
RNAs (lncRNAs) and novel lncRNA genes are be-
ing identified at rapid pace. To streamline these
efforts, we created LNCipedia, an online reposi-
tory of lncRNA transcripts and annotation. Here, we
present LNCipedia 3.0 (http://www.lncipedia.org), the
latest version of the publicly available human lncRNA
database. Compared to the previous version of LNCi-
pedia, the database grew over five times in size, gain-
ing over 90 000 new lncRNA transcripts. Assessment
of the protein-coding potential of LNCipedia entries
is improved with state-of-the art methods that include
large-scale reprocessing of publicly available pro-
teomics data. As a result, a high-confidence set of
lncRNA transcripts with low coding potential is de-
fined and made available for download. In addition,
a tool to assess lncRNA gene conservation between
human, mouse and zebrafish has been implemented.
INTRODUCTION
Over the past decade long non-coding RNAs (lncRNAs)
have emerged as a large class of functional non-coding
RNAs (ncRNAs) (1). Defined as ncRNA transcripts longer
than 200 nucleotides, lncRNAs have been shown to func-
tionmainly as transcriptional regulators by interactionwith
other biomolecules, such as proteins (2–4) and microR-
NAs (5). They are involved in a wide range of processes
including cardiac development (6), dosage compensation
(7,8) and cancer (2,9–10). Several specialist databases con-
cerning lncRNA have been developed. Well-known exam-
ples are lncRNAdb, which focuses on lncRNAs with de-
scribed functions (11), and NONCODE (12,13). In addi-
tion to these general lncRNA databases, databases that de-
scribe specific lncRNA subclasses have been compiled as
well. LncRNAdisease contains lncRNAs with published
disease associations (14) while lncRNAs targeted by mi-
croRNAs can be found in DIANA-LncBase (15).
Distinguishing coding from ncRNA sequences is an im-
portant step, both in the ncRNA and the protein research
field. Classic approaches are based on either open reading
frame (ORF) length, ORF conservation or structural pro-
tein domains (16). Recent computational methods make
use of more complex features or machine learning ap-
proaches. Notable examples are the Coding-Potential Cal-
culator (CPC), Coding-Potential Assessment Tool (CPAT)
and PhyloCSF. CPC utilizes a support vector machine
trained on features that describe long, high-quality ORFs
with sequence similarity (BLASTX) to known proteins (17).
CPAT is a logistic regressionmodel that only uses sequence-
derived features, such as ORF size, codon and hexamer us-
age bias (18). In contrast to CPC and CPAT, PhyloCSF
employs codon substitution frequencies in whole-genome
multi-species alignments and maximum likelihood trees to
distinguish between coding and non-coding loci (19).
ORF length is either directly or indirectly used in all
these computational prediction methods yet ORFs yield-
ing short peptides (<100 amino acids) are difficult to pre-
dict. The discovery of functional peptides shorter than
100 amino acids, like the Drosophila gene tarsal-less (tal),
thus raised the possibility that several lncRNAs are actu-
ally misclassified protein-coding genes encoding micropep-
tides (20,21). As small ORFs can also occur by chance
in long transcripts, many well-described lncRNAs harbor
non-functional ORFs (22). In addition to small ORFs, the
in silico prediction of coding ORFs is further complicated
by the existence of non-canonical (non-AUG) start codons
(23).
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Figure 1. LNCipedia has grown substantially since itsfi rst release. Thefi rst version (41) was based on sequences and annotation from three different
sources and was made available to the public in 2012. For the 2013 release of LNCipedia (unpublished), no additional sources were used, but the different





























Figure 2. Many lncRNA loci are conserved in mouse or zebrafish. Locus
conservation is a novel tool to determine the orthologous locus of a human
lncRNA in another species. When the order of thefl anking protein-coding
genes is conserved in another species, the lncRNA locus is considered con-
served. The majority of the conserved loci in zebrafish are also conserved
in mouse, this fraction is depicted in gray.
Experimental procedures to detect translated ORFs and
their products have been developed as well. One such
method is referred to as ribosome profiling and is based on
deep sequencing of ribosome-protected mRNA fragments.
Although many ncRNAs show ribosome occupancy, by us-
ing initiation-specific translation inhibitors in combination
with ribosome profiling, researchers were able tomap trans-
lation initiation sites (TIS) with base pair resolution and im-
prove the detection of true ORFs (23,24). Other researchers
were able to use the periodicity of ribosome movement on
the mRNA to define actively translated ORFs (25). In ad-
dition to ribosome profiling, mass spectrometry has been
applied in the search for novel peptides arising from lncR-
NAs (26,27). Several authors report small numbers of (mi-
cro) peptides arising from lncRNAs using either ribosome
profiling or mass spectrometry. The debate on the putative
function and total number of these peptides is still ongoing
(26–28).
Here, we report on LNCipedia 3.0, the latest version of
our publically available lncRNA database. In version 3.0,
our major improvement is the evaluation of protein-coding
potential with state-of-the-art algorithms and data sets. As
such we have generated a high-confidence data set that ex-
cludes lncRNAs with possible protein-coding potential. In
addition, a new tool to assess the conservation of lncRNA
genes has been implemented. The database content has been
updated and now contains over five times the number of
transcripts compared to thefi rst version.
MATERIALS AND METHODS
Locus conservation
The upstream and downstream protein-coding genes that
flank a human lncRNA gene are queried in the public En-
sembl (29) MySQL database (version 73). For both genes,
the orthologs in mouse and zebrafish are obtained using
the Ensembl Compara API (version 73). If any pair of or-
thologs are neighboring genes, the locus is reported as con-
served.
PhyloCSF
Whole-genome alignments of 46 species are obtained from
theUCSCwebsite (30) and processed using the PHAST (31)
package (version 1.3) to obtain the required input format
for PhyloCSF (19). To validate our workflow, we bench-
marked PhyloCSF with transcripts annotated in Ensembl
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(version 75). Transcripts with biotype ‘lincRNA’ or ‘anti-
sense’ (20 320 transcripts) serve as negative set while tran-
scripts with biotype ‘protein coding’ and an annotated cod-
ing sequence (36 959 transcripts) serve as positive set.
TIS
Ribosome profiling sequencing data of HEK-293 cells
treated with cycloheximide (CHX) and lactimidomycin
(LTM) were processed (24). Two technical replicates of
both treatments were pooled (Bioproject http://www.ncbi.
nlm.nih.gov/bioproject/PRJNA171327: runs SRR618770
and SRR618771 for CHX and runs SRR618772 and
SRR618773 for LTM).
The reads werefi rst clipped to remove their 3′ cloning
adaptor sequence using the FASTX-Toolkit (fastx clipper
tool). Unclipped and clipped reads shorter than 25 nt
were discarded. The remaining reads were mapped us-
ing the RNA-seq STAR aligner (32), sequentially us-
ing indices based on the following sequences: (i) Phix
genome (widely used as a quality control for Illumina
sequencing runs), (ii) Homo sapiens rRNA (Refseq IDs
NR 003285.2, NR 003286.1, NR 003287.1, NR 023363.1)
and (iii) the human reference genome (downloaded
from the igenomes repository http://support.illumina.com/
sequencing/sequencing software/igenome.ilmn, using the
H. sapiens genome build GRCh37 and Ensembl annota-
tion version 70). The human STAR index was built tak-
ing into account the splice site annotation from Ensembl.
Only uniquely mapped reads that are between 28 and 35 nt
long were retained. Footprint alignments were assigned to a
specific P-site nucleotide based on the fragment length (the
5′ offset is set to respectively 12, 13 or 14 for profiles with
length ≤ 30 nt, 31–33 nt, or ≥ 34 nt (23)).
PRoteomics IDEntifications (PRIDE) reprocessing
The processing pipeline consists of three major modules.
Thefi rst module is based on the PRIDE automated spec-
trum annotation pipeline (pride-asap) (33), and is used
to reverse engineer the original search parameters from
submitted data. The key parameters extracted by pride-
asap in this stage are the allowable mass errors, the post-
translational modifications (PTMs) to consider, and the
enzyme used. Recent developments in this module have
greatly improved the PTM inference by considering the
modifications found in the PSI-mod (34) and Unimod (35)
databases, as well as the frequency of occurrence of these
modifications. Two thresholds are calculated based on this
information, with thefi rst one serving as a lower threshold
to exclude very low abundance modifications while the sec-
ond threshold is used to determine whether a sufficiently
abundant modification is to be considered as either variable
orfi xed. A second development has been the impromptu de-
termination of the protease used in the original experiment.
Instead of assuming the use of trypsin, the pride-asap mod-
ule now calculates the most likely enzyme based on all re-
ported peptide sequences reported in PRIDE for that exper-
iment. Overall, these updates to the module allow a reduc-
tion in search space to consider, providing faster processing
times and leaving less room for false-positive matches.
The second module handles the peptide-to-spectrum
matching, relying on SearchGUI (36) to automatically run
multiple search engines in parallel; in this case OMSSA (37)
and X!Tandem (38). SearchGUI is configured to use the
target/decoy approach (39), where both the original (tar-
get) sequence database is searched, but also a reversed (de-
coy) version of that database. Matches from the latter can
then be used to determine a false discovery rate (FDR) (39).
The third andfi nal module uses PeptideShaker
(http://peptide-shaker.googlecode.com) and the
compomics-utilities library (40) to collect, process and
analyze the results generated by SearchGUI.
RESULTS
LNCipedia 3.0 content
LNCipedia 1.0 (41) combined sequences and annotation
from three different public resources, namely, Ensembl
(29,42), Human body map lincRNAs (43) and the lncRNA
database (11). In LNCipedia version 3.0, we have comple-
mented these resources with four additional public data
sets (Table 1). Two of these data sets are obtained from
databases (44,45), and two from lncRNA research articles
describing RNA sequencing workflows and reporting on
novel lncRNAs (46,47). As with LNCipedia 1.0, redundant
transcripts are merged into the same record. The result of
this extension and integration of sources is that LNCipedia
3.0 represents a more than 5-fold increase in transcript con-
tent over version 1.0 (Figure 1). The majority of these tran-
scripts (80%) is found in new loci and as such give rise to
novel lncRNA genes.
In LNCipedia 1.0 we introduced a universal lncRNA
nomenclature to overcome the confusion caused by the use
of different identifiers by different authors and databases.
As was suggested by others, we named lncRNAs after
neighboring protein-coding genes on the same strand (48).
In LNCipedia 3.0, we hold true to this strategy. Existing
genes are expandedwhen novel transcripts have overlapping
exons and new genes are created when a transcript does not
share exonic sequence with any existing gene.
Locus conservation
The identification of orthologous lncRNAs is an important
step for animal modeling and functional research across
species. Conservation of gene order is a straightforward
metric often used in comparative genomics. We applied the
concept of gene order conservation to determine the orthol-
ogous locus of a lncRNA in another species. Using the En-
sembl Compara API, we have assessed the conservation in
the order of thefl anking protein-coding genes. Currently,
orthologs for non-coding genes are not as well annotated
as for protein-coding genes,fl anking non-coding genes were
therefore not taken into account. When the order is con-
served in mouse or zebrafish we report the locus as con-
served. In this way, wefi nd locus conservation for 55% of
the human lncRNA genes in mouse, and for 27% in ze-
brafish (Figure 2). The majority of the conserved loci in ze-
brafish are also conserved in mouse, as one would expect.
While locus conservation is no proof for the functional con-
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Table 1. Overview of data sources contributing to lncRNA content in LNCipedia 3.0
Source Version Number of transcripts
Ensembl (42) 75 23 498
Refseq (44) March 2014 6917
Nielsen et al. (46) 7656
Hangauer et al. (47) 5339
NONCODE (45) 4 93 164
LNCipedia (41) 1.0 21 504
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Figure 3. Different methods suggest contamination of coding sequences in lncRNA data sets. (a) PhyloCSF benchmarking and score distributions. We
can observe a considerable difference between the score distributions of coding and non-coding transcripts in the Ensembl data set. In addition, while the
great majority of LNCipedia is presumably non-coding, it also contains a fraction of transcripts with a PhyloCSF score in the coding range. (b) Transcripts
with a TIS have a significantly higher PhyloCSF score (Mann–Whitney U test) compared to other transcripts. (c) Several public lncRNA resources suffer
from considerable contamination with protein-coding sequences. The percentage of transcripts with PhyloCSF score greater than 41 is shown for the
different sources in LNCipedia 3.0. Two sources alreadyfi ltered with PhyloCSF are depicted in gray. In the case of RefSeq, only entries with property
“biomol ncrna lncrna” were considered.
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LNCipedia 3.0
113,513 transcripts
- Bazzine et al., 2014 smORFs
 = 113,260 transcripts
- Lee et al., 2012 TIS
= 109,133 transcripts
- PhyloCSF score > 41
= 81,840 transcripts
 = high-confidence set
- PRIDE PSMs
= 80,216 transcripts
Figure 4. Transcripts with a likely coding potential are removed in the def-
inition of a high-confidence set. Transcripts containing small ORFs (25),
TIS (24), PhyloCSF score greater than 41 or PSMs with an identification
confidence higher than 90% are excluded.
servation of the lncRNA itself, it may serve afi rst step in
finding the orthologous lncRNA.
Protein-coding potential
For collection of lncRNA transcript sequences, we rely on
public data sets that are often contaminated with small
numbers of transcripts harboring coding ORFs (25,26).
While we already presented several measures to assess this
problem (41), we further expanded these with state-of-the-
art tools and included additional lncRNA transcript data
sets. One such measure is the PhyloCSF (19) score. We have
benchmarked PhyloCSF using Ensembl transcripts and we
have determined 41 as an optimal threshold for the Phy-
loCSF score resulting in a precision of 95% and sensitiv-
ity of 91% (Supplemental Material and Figures). From the
empirical cumulative distribution (Figure 3a) it is apparent
that LNCipedia most likely contains a considerable frac-
tion of protein-coding sequences. When applying our pre-
computed cutoff, these transcripts add up to about 26% of
the collection. Figure 3c shows the distribution of these pu-
tative coding transcripts among the different sources used
for LNCipedia. It is clear that some lncRNA data sets suf-
fer more from contamination of coding sequences than oth-
ers. Strikingly, nearly 50% of Refseq annotated non-coding
sequences are predicted to be coding according to the Phy-
loCSF score cutoff. It is no surprise that the lowest num-
ber of coding sequences is observed in Cabili et al. and
Hangauer et al. as these studies applied PhyloCSF as afilter
in their workflow.
Another measure to assess protein-coding potential is the
use of ribosome profiling to map TIS. When we map the
TIS observed in HEK-293 (24) to LNCipedia entries, we
find 4154 trancripts with at least one TIS. Of note, these
transcripts have significantly higher PhyloCSF scores (Fig-
ure 3b), which is a good validation of both methods.
PRIDE
Similar to the rapid growth of LNCipedia, the submission
of mass spectrometry data to the PRIDE repository has
flourished as well (49). While these increased collections of
lncRNAs and mass spectrometry data provide even more
means to detect potentially coding lncRNAs, they also re-
quire much more compute power to process. The only way
to analyze these data in a timely fashion is to make use of
parallelization on a compute cluster or through grid com-
puting (50). We have therefore set up such a grid environ-
ment based on dedicated hardware running a collection of
Linux virtual machines, allowing us to re-analyze the full
human complement of PRIDE in under a week.
At the time of writing, the pipeline has been run on
2493 PRIDE experiments, containing 39 463 035 fragmen-
tation mass spectra and covering all 68 annotated human
tissues in the public repository. This resulted in a total of
8 064 657 peptide-to-spectrum matches (PSMs), of which
747 305 were matched to lncRNAs in LNCipedia (393 859
matched the target database and 353 446 matched the de-
coy database). Of these PSMs, 18 929 target sequences (rep-
resenting 2040 transcripts, from 1770 genes) had an iden-
tification confidence higher than 90% (in contrast to only
2001 decoy sequences that had such a high confidence).
Of note, the estimation of the FDR remains a complex is-
sue in these very broad searches (51,52), and care should
be taken to interpret these results. Indeed, as supplemen-
tary Figures S1 and S2 illustrate, while the confidence com-
pares reasonably well with the estimated FDR, especially
at higher confidences (higher than 90%), the evolution of
the FDR toward the higher confidences is very different
between the UniProtKB-SwissProt-derived identifications
and the lncRNA matches.
No significantly higher PhyloCSF score was found for
transcripts containing PSMs with identification confidence
higher than 90%. In addition, no significant overlap is ob-
served between the set of transcripts identified in PRIDE
and the sets containing TIS and smORFs. This observation
illustrates the very unique nature of the PRIDEanalysis and
strongly suggests its ability to detect coding potential not
predicted by other methods.
HIGH-CONFIDENCE SET
Since LNCipedia contains a non-negligible number of pu-
tative coding transcripts, we propose afi ltering strategy to
create a stringent or high-confidence data set. Four groups
of putative coding transcripts are removed (Figure 4, Sup-
plementary Figure S3). The first group consists of 253 lncR-
NAs containing small ORFs (smORFs) (25). Bazzini et al.
developed an approach to detect smORFs using ribosome
profiling whereby the periodicity of ribosome movement
on actively translated ORFs is used to distinguish cod-
ing from non-coding sequences. A second approach to ap-
ply ribosome profiling in the quest for novel coding RNAs
has been described by Lee et al. (24). Using LTM, a ri-
bosome inhibitor specific to initiating ribosomes, TIS were
mapped in HEK-293 cells. Note that 4127 lncRNA tran-
scripts containing at least one TIS are thus withdrawn.
While these transcripts have a good change to give rise to
peptides, it is important to consider that a negative result
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does not guarantee the opposite. The transcript may not be
expressed or translated in the sample. The nextfi ltering step
is based on PhyloCSF (19). As discussed earlier, this algo-
rithm can distinguish between coding and non-coding se-
quences with high accuracy. As such, 27 293 transcripts with
a PhyloCSF score higher than 41 are discarded. Finally, the
2040 PSM containing transcripts from the PRIDE repro-
cessing pipeline are excluded as well. The resulting set of
80 216 transcripts (71% of LNCipedia 3.0) representing 48
028 genes (76%) is referred to as ‘high-confidence set’ and
is available for download on the LNCipedia website.
CONCLUSION AND FUTURE DIRECTION
With over 90 000 new transcripts, LNCipedia content in-
creased 5-fold since its first publication in 2012. This makes
it to our knowledge the largest publicly available human
lncRNA resource. Furthermore, we improved the evalua-
tion of coding potential with state-of-the-art algorithms,
published data sets and an improved PRIDE reprocessing
pipeline. In addition, we have developed a locus conserva-
tion analysis tool, which can aid in the search for lncRNA
orthologs or prioritarization of lncRNAs for animal stud-
ies.
As in the previous years, LNCipedia will be updated
when new lncRNA data sets are available. With the arrival
of a new human reference genome (GRCh38), an impor-
tant improvement to the database will be remapping chro-
mosomal positions to this new reference genome. We will
also continue to automatically run searches against the ever-
growing contents of the PRIDE database on a routine basis.
Furthermore, we will improve the specificity of the PRIDE
searches by taking possible contamination from viral se-
quences into account.
In conclusion, LNCipedia 3.0 provides significant im-
provements over the previous version in terms of data con-
tent and data annotation.
AVAILABILITY
LNCipedia 3.0 can be accessed trough a web interface at
www.lncipedia.org. Exports are available in FASTA, GFF,
GTF or BED format for both the entire lncRNA collec-
tion and the high-confidence set. In addition, Integrative
Genome Viewer (IGV) users have the option of loading an
IGV optimized data set directly in the application. As in
version 1.0, the database can be queried by chromosomal
position or (partial) sequence. We encourage the lncRNA
research community to contribute to LNCipedia by sub-
mitting newly discovered lncRNAs and by adding PubMed
literature records to existing entries using the web interface.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Over' the' past' decade,' long' nonPcoding' RNAs' (lncRNAs)' have' emerged' as' novel'
functional' entities' of' the' eukaryotic' genome.' However,' the' scientific' community'
remains' divided' over' the' amount' of' true' nonPcoding' transcripts' among' the' large'
number'of'unannotated' transcripts' identified'by' recent' large' scale'and'deep'RNAP







eukaryotic' genome' outside' of' annotated' proteinPcoding' loci.'Most' of' these' novel'
transcripts'are' long'(>'200'nucleotides),' lack' large'open'reading'frames'(ORFs)'and'
homology' to' annotated' proteinPcoding' genes1.' Termed' long' nonPcoding' RNAs'
(lncRNAs),'these'transcripts'comprise'a'vast,'diverse'and'largely'unexplored'class'of'
RNA,'outnumbering'any'other'class'of'genetic'entities'in'the'human'genome2.'Those'
that' have' been' studied' in' detail' play' important' roles' in' a' wide' range' of' cellular'
processes' during' normal' development' and' in' homeostasis' and' disease,' including'
cancer3.'
Similar'to'lncRNAs,'short'open'reading'frame'(sORF)Pencoded'polypeptides'(SEPs)'or'
micropeptides' have' gained' increased' attention' over' the' past' few' years.' While'









fragments)'promised' to'provide'evidence' for' (the' lack'of)' translation'of'expressed'
ORFs,' much' is' still' open' to' interpretation.' Numerous' studies' report' substantial'
ribosome'occupancy'of'lncRNA'transcripts9P12.'The'striking'similarities'in'the'pattern'
and' size' of' ribosome' protected' fragments' covering' proteinPcoding' transcripts' and'
lncRNAs' have' led' some' researchers' to' conclude' that' up' to' 90%' of' the' lncRNA'
transcriptome' bears' coding' ORFs10.' Other' researchers' report' much' more'
conservative' numbers11P14.' For' instance,' if' the' relative' abundance' of' ribosomes'
before' and' after' stop' codons' (termed' ribosome' release)' is' used' to' discriminate'
between'proteinPcoding' and'nonPcoding' transcripts,' only' a' few'novel' coding'ORFs'
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are' found11.'When' taking' into'account' the'phased'movement'of' ribosomes'across'
translated' ORFs,' only' a' small' number' of' novel' peptides' arising' from' transcripts'
annotated' as' lncRNAs13' are' identified.' Different' research' groups' have' thus'
developed'different'metrics'and'methodologies' to'detect'coding'ORFs' in' ribosome'
profiling'data.'Without'a'consensus,'the'true'coding'potential'of'lncRNA'transcripts'
remains'open'to'speculation.'
Mass' spectrometry' is' often' considered' as' the' gold' standard' in' detection' and'
characterization' of' proteins' or' peptides.' So' far,' few' studies' have' turned' to'mass'
spectrometry' to' study' micropeptides' and' lncRNAPencoded' proteins.' Reported'
numbers'vary'from'less'than'100'up'to'1,600'in'human15P18.'Compared'to'the'more'
than'60,000'reported' lncRNA'genes2,15,' these'numbers'are'fairly' low'and'definitely'
much'lower'than'those'reported'by'various'ribosome'profiling'studies.'
This'discrepancy'in'the'reported'amounts'of'potentially'coding'lncRNAs'is'the'source'
of' spirited' discussion' in' the' field.' Indeed,' a' resolution' of' this' conflict' has' direct'
relevance'for'further'investigations'into'the'biological'roles'of'lncRNAs.'
The' most' direct' observation' of' coding' lncRNAs' is' the' actual' detection' by' mass'
spectrometry' based' proteomics' of' the' encoded' proteins.' As' such,' the' absence' of'
large'amounts'of'detected'lncRNAPderived'proteins'strongly'hints'at'a'limited'coding'




characterize' lncRNAPencoded' proteins' based' on' a' detailed' yet' exhaustive'
reprocessing'of' very' large' amounts'of' public' proteomics'data.'Our' findings' clearly'
show' that' there' are' no' obvious' technical' reasons' why' mass' spectrometry' would'




THE' INFLUENCE' OF' PROTEIN' COMPOSITION' ON' DETECTABILITY'
BY'MASS'SPECTROMETRY'
Mass' spectrometry' enables' highPthroughput' protein' identification' in' complex'
samples.' However,' there' is' some' controversy' regarding' the' limitations' of' this'
technique' in' terms' of' detectability' of' peptides' and' thus,' by' extension,' proteins.'
Several'potential'causes'have'been'proposed,'including'biases'due'to'the'size'of'the'
protein'sequence,' the'amino'acid'composition,' the'abundance,'and' the'halfPlife'of'
proteins19P21.' Here,' we' investigate' these' presumed' issues' and' identify' potential'
reasons' as' to' why' certain' predicted' ORF' products' evade' detection.' The' applied'
strategy'revolves'around'the'reprocessing'of'publicly'available'data'in'PRIDE22,'one'
of' the' world’s' leading' mass' spectrometry' repositories23.' Sequence' database'
searches'were' performed' using' an' automated' reprocessing' pipeline,' consisting' of'
pridePasap24'for'the'detection'of'data'set'specific'parameters,'SearchGUI25'to'match'









in' which' a' protein' was' identified,' was' used' to' indicate' the' number' of' times' the'
protein' was' observed.' Q8WZ42,' the' megadalton' protein' titin,' represented' by' its'
canonical' isoform'of' 34,350' residues,'was' identified' 298' times' in' 183' assays.' This'
indicates'that'large'proteins'are'picked'up'despite'their'length,'as'is'to'be'expected'
due' to' the' relatively' higher' number' of' potential' MS/MSPidentifiable' peptides'
following'enzymatic'cleavage'of'larger'proteins.'At'the'same'time,'short'proteins'are'
also'frequently' identified'across'a'broad'range'of'assays'(Table'1).' It' is'noteworthy'
that'out'of'20,207'human'entries'in'UniProtKB/SwissProt,'only'36'–(mainly)'tissue'or'
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P62328' TMSB4X' 44' 4921.46' 787' 287'
P63313' TMSB10' 44' 4894.48' 366' 229'
Q8N4H5' TOMM5' 51' 6035.31' 88' 70'
P62891' RPL39' 51' 6275.49' 109' 52'
Q59GN2' RPL39P5' 51' 6322.59' 107' 51'
Q5VTU8' ATP5EP2' 51' 5806.87' 53' 43'
P56381' ATP5E' 51' 5648.57' 53' 43'
Q96IX5' USMG5' 58' 6326.38' 112' 86'
P62861' FAU' 59' 6647.86' 248' 141'
P13640' MT1G' 62' 6647.86' 71' 47'
'
Table'1:' The( ten( shortest( human(proteins( identified( by( reprocessing( of( the( reprocessed(
PRIDE(data.(
'
A' second' feature' that' could' impose' a' bias' on' protein' detection' using' mass'
spectrometry' is' the' amino' acid' sequence' composition.' The' existence' of' such' a'
potential'bias'was'investigated'by'comparing'the'composition'of'peptides'that'have'




in' PRIDE' and' in& silico' obtained' peptide' sequences' from' the' in& silico' digest' of'
UniProtKB/SwissProt'were'filtered'to'sizes'between'5'and'30'amino'acids,'which' is'
the' common' range' of' observed' peptide' lengths' in' practice29.' The' amino' acid'






very' different.' The' somewhat' higher' occurrence' rates' for' R' and' K' in' the'
experimental'data'are'most'likely'related'to'the'fact'that'these'residues'are'strong'





Figure(1:' Comparison' between' theoretical' (UniProtKB/SwissProt)' and' observed'
(reprocessed'PRIDE'data)' peptide' sequence'amino'acid' composition' for'human'
data'from'PRIDE'and'UniProtKB/SwissProt.''
'
Another' important' property' that' can' affect' detection' by' mass' spectrometry' is'
protein'(and'thus'peptide)'abundance'in'the'sample.'Although'there'are'examples'of'




by'Anderson' and'Hunter31' that' reports' empirically' obtained'protein' quantification'
values' in' human' blood' plasma.' Reprocessing' of' the' subset' of' PRIDE' data' sets'















where' halfPlife' values' for' murine' proteins' are' reported32.' Because' PRIDE' also'
contains'murine'data,'extensive'reprocessing'of'these'murine'data'sets'against'the'
mouse' complement' of' the' UniProtKB/SwissProt' database'was' performed' and' the'





reported' by' Schwanhäusser' et& al.' The' size' of' the' bubble' corresponds' to' the'
number'of'PRIDE'assays'in'which'the'protein'was'identified.'
'
In' addition,' we' calculated' the' NPterminal' instability' index' of' human' proteins' as'
described'by'Guruprasad'et&al.33.'This'metric'is'based'on'the'dipeptide'composition'
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of' a' protein' and' provides' a' crude' estimation' of' protein' halfPlife' when' largePscale'
experimental' data' are' lacking,' as' is' the' case' for' human' proteins.' The' underlying'
assumption'is'that'a'protein’s'halfPlife'correlates'negatively'to'its'relative'instability.'
We' therefore' compared' the' calculated' instability' indices' for' all' proteins' in' the'
human'complement'of'UniProtKB/SwissProt'with'those'calculated'for'the'identified'
proteins' from' the' human' data' sets' in' PRIDE.' Only' a' minor' deviation' is' revealed'
between' the' instability' index' distributions' of' observed' and' theoretical& proteins,'








LNCRNA' EXPRESSION'AND' COMPOSITION' SHOW'NO' INDICATION'
OF'CODING'POTENTIAL'
The' expression' profile' of' lncRNAs' differs' extensively' from' that' of' protein' coding'
mRNAs'(Figure'4a).'LncRNAs'are'generally'expressed'at'a' lower'level'and'are'more'
abundant' in' the' nucleus.' While' mRNAs' are' transported' to' the' cytoplasm' for'
ribosomal'translation,'several'lncRNAs'have'a'documented'function'in'the'nucleus34.'
As' such,' the' nuclear' enrichment' of' lncRNAs' suggests' a' nonPcoding' role' for' the'
majority'of'the'lncRNA'transcripts.'
We'have'observed' that' very' low'protein' abundance' can'hamper' the'detection'by'
mass' spectrometry' (Error!( Reference( source( not( found.2)' and' lncRNAs' are'




dataset1' (see' Supplementary' Material' for' details).' While' the' average' expression'
level'of'lncRNAs'is'below'that'of'protein'coding'genes,'the'expression'range'is'very'
similar' (Figure' 4b).' In' addition,' a' substantial' number' of' lncRNAs' are' expressed' at'
levels'similar'to'typical'mRNA'transcripts.'To'evaluate'the'protein'detectability'as'a'
function' of' its' mRNA' expression,' we' compared' mRNA' expression' levels' to' the'
normalized' spectral' abundance' factor' (NSAF+)36' of' the' corresponding'protein.' The'
expression'level'is'defined'as'the'maximally'observed'RPKM'(reads'per'kilobase'per'
million'mapped' reads)' for' a' particular'mRNA' across' 11' cell' lines' in' the'GENCODE'
dataset.' The'maximally'observed'NSAF+' for' each'protein' from' the'4,413'assays' in'
PRIDE'that'originate'from'these'cell'lines'is'reported.'The'NSAF+'and'RPKM'show'a'
low' but' significant' correlation' (Spearman' ρ' =' 0.32,' pPvalue' <' 0.01),' which' is'
particularly'apparent' in' the'higher'expression' ranges' (Figure'4c).' Importantly,'even'
though'low'abundant'proteins'are'more'difficult'to'detect,'detected'proteins'cover'





density' plot' of' lncRNA' and' mRNA' expression' levels' and' subcellular' localization.'
The'enrichment'of'nuclear'over' cytosolic'expression'versus' the'expression' in' the'
wholePcell' extract' is' shown.' Selected' lncRNA' and' protein' coding' genes' are'
depicted.'Especially'low'abundant'lncRNAs'show'nuclear'enrichment'compared'to'
mRNAs' (adapted' from' Djebali' et& al.1)' b)' WholePcell' expression' distribution' for'
lncRNAs'and'mRNAs.'Although' lncRNAs'are'generally'expressed'at' lower' levels,'a'
substantial'overlap'is'observed.'c)'Normalized'spectral'abundance'factor'(NSAF)'of'




The' fact' remains' that' most' (if' not' all)' lncRNAs' contain' canonical' ORFs.' While'
predictions' classify' these' as' nonPcoding' (hence' the' annotation' as' lncRNA),' it' is'
conceivable'that'these'ORFs'represent'recent'evolutionary'adaptations'and'are'thus'
difficult'to'detect'by' in&silico'analyses.'To'evaluate' if' lncRNA'ORFs'are'evolutionary'
retained' or' products' of' random'nucleotide' progression,'we' examined' the' relative'
size'of'these'ORFs.'By'using'the'reverse'complement'of'the'sequence'as'a'control,'it'
is' obvious' that' mRNA' ORFs' are' much' larger' than' random' ORFs' in' the' reverse'
complement'sequence'(see'Supplementary'Material'for'details).'In'contrast,'lncRNA'
ORFs'do'not'differ' in' size' from' randomly'occurring'ORFs,' suggesting' that' they'are'
indeed'the'product'of'random'nucleotide'progression.'In'addition,'it'was'previously'




the' reverse' complement' sequence' as' a' control,' it' is' apparent' that' lncRNA' (as'











murine' proteomes' to' eliminate' possible' biases' of' mass' spectrometry' based'
proteomics' in' detecting' lncRNAPderived' proteins.' Our' analyses' reveal' that' the'
detection' of' proteins' by'mass' spectrometry' displays' only' limited' bias,' relating' to'
proteins'with'very'low'abundance'and/or'very'short'sequence'lengths'(shorter'than'
44' amino' acids).' Nevertheless,' it' should' be' noted' that' specialized' methods' can'
circumvent'the'observed'protein'detection'biases.'Targeted'sampling'of'less'studied'
tissues'may'still'reveal'the'existence'of'lncRNAPencoded,'tissue'specific1'translation'
products.' Short' translation' products' can' be' picked' up' using' peptidomics'




Even' though' mass' spectrometry' has' its' limitations' in' the' detection' of' very' low'
abundant'or'very'small'proteins,'we'firmly'demonstrate'here'that'these'limitations'




thus' unlikely' that' the'majority' of' the' current' lncRNA' annotation' consists' of'missP












































































































of'data' through'the'PRIDE'webservice' (Reisinger&et&al.,'2015),' (ii)' the'extraction'of'














in' PRIDE' using' pridePasap.' These' parameters' include' precursor' and' fragment' ion'
mass' accuraccies,' the'most' probable'modifications' and' their' occurrence' rate,' the'
used' digestion' enzyme,' and' the' amount' of' missed' cleavages.' In' the' uncommon'
event'that'no'identifications'were'reported'in'the'PRIDE'assay,'default'settings'were'




by' pridePasap.' Three' search' engines'were' enabled' in' SearchGUI:' X!Tandem' (Craig'
and' Beavis,' 2004),'MyriMatch' (Tabb& et& al.,' 2007),' and'MSPGF+' (Kim' and' Pevzner,'
2014),'with'matching' performed' against' the' human'or'mouse' complement' of' the'
RESULTS' 97'










were' obtained' from' the' Gene' Expression' Omnibus' (GEO)' website.' The' dataset'
comprises' RNA' sequencing' in' eleven' cell' lines' and' three' cell' fractions.' Average'
RPKM'values'are'extracted' from'the'public'datasets.'Further'analysis' is'performed'
using' the' statistical' environment' R' and' the' ggplot2' and' dplyr' packages.' Using'
Ensembl' identifiers,' the' transcripts' are' classified' as' protein& coding' if' the'







custom' java' code' and' the' NSAF' values' are' matched' to' the' corresponding' mRNA'





accession( cell(line( fraction( Filename(
GSM758559' GM12878' cell' GSM758559_hg19_wgEncodeCshlLongRnaS
eqGm12878CellPapGeneGencV7.txt'
GSM758560' GM12878' cytosol' GSM758560_hg19_wgEncodeCshlLongRnaS
eqGm12878CytosolPapGeneGencV7.txt'
GSM758563' HUVEC' cell' GSM758563_hg19_wgEncodeCshlLongRnaS
eqHuvecCellPapGeneGencV7.txt'
GSM758564' A549' cell' GSM758564_hg19_wgEncodeCshlLongRnaS
eqA549CellPapGeneGencV7.txt'
GSM758565' HUVEC' nucleus' GSM758565_hg19_wgEncodeCshlLongRnaS
eqHuvecNucleusPapGeneGencV7.txt'
GSM758566' H1PhESC' cell' GSM758566_hg19_wgEncodeCshlLongRnaS
eqH1hescCellPapGeneGencV7.txt'
GSM758568' HepG2' nucleus' GSM758568_hg19_wgEncodeCshlLongRnaS
eqHepg2NucleusPapGeneGencV7.txt'
GSM758569' HUVEC' cytosol' GSM758569_hg19_wgEncodeCshlLongRnaS
eqHuvecCytosolPapGeneGencV7.txt'
GSM758570' H1PhESC' cytosol' GSM758570_hg19_wgEncodeCshlLongRnaS
eqH1hescCytosolPapGeneGencV7.txt'
GSM758574' H1PhESC' nucleus' GSM758574_hg19_wgEncodeCshlLongRnaS
eqH1hescNucleusPapGeneGencV7.txt'
GSM758575' HepG2' cell' GSM758575_hg19_wgEncodeCshlLongRnaS
eqHepg2CellPapGeneGencV7.txt'
GSM758576' HepG2' cytosol' GSM758576_hg19_wgEncodeCshlLongRnaS
eqHepg2CytosolPapGeneGencV7.txt'
GSM765386' GM12878' nucleus' GSM765386_wgEncodeCshlLongRnaSeqGm
12878NucleusPapGeneGencV3c.txt'
GSM765387' K562' nucleus' GSM765387_wgEncodeCshlLongRnaSeqK56
2NucleusPapGeneGencV3c.txt'
GSM765388' MCFP7' cell' GSM765388_wgEncodeCshlLongRnaSeqMcf
7CellPapGeneGencV3c.txt'
GSM765399' NHEK' nucleus' GSM765399_wgEncodeCshlLongRnaSeqNhe
kNucleusPapGeneGencV3c.txt'
GSM765400' NHEK' cytosol' GSM765400_wgEncodeCshlLongRnaSeqNhe
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kCytosolPapGeneGencV3c.txt'
GSM765401' NHEK' cell' GSM765401_wgEncodeCshlLongRnaSeqNhe
kCellPapGeneGencV3c.txt'
GSM765402' HeLaPS3' cell' GSM765402_wgEncodeCshlLongRnaSeqHela
s3CellPapGeneGencV3c.txt'
GSM765403' HeLaPS3' nucleus' GSM765403_wgEncodeCshlLongRnaSeqHela
s3NucleusPapGeneGencV3c.txt'
GSM765404' HeLaPS3' cytosol' GSM765404_wgEncodeCshlLongRnaSeqHela
s3CytosolPapGeneGencV3c.txt'
GSM765405' K562' cell' GSM765405_wgEncodeCshlLongRnaSeqK56
2CellPapGeneGencV3c.txt'
GSM840137' K562' cytosol' GSM840137_hg19_wgEncodeCshlLongRnaS
eqK562CytosolPapGeneGencV7.txt'
GSM981244' IMR90' cytosol' GSM981244_hg19_wgEncodeCshlLongRnaS
eqImr90CytosolPapGeneGencV10.txt'
GSM981245' MCFP7' nucleus' GSM981245_hg19_wgEncodeCshlLongRnaS
eqMcf7NucleusPapGeneGencV10.txt'
GSM981246' A549' cytosol' GSM981246_hg19_wgEncodeCshlLongRnaS
eqA549CytosolPapGeneGencV10.txt'
GSM981247' A549' nucleus' GSM981247_hg19_wgEncodeCshlLongRnaS
eqA549NucleusPapGeneGencV10.txt'
GSM981248' IMR90' nucleus' GSM981248_hg19_wgEncodeCshlLongRnaS
eqImr90NucleusPapGeneGencV10.txt'
GSM981249' IMR90' cell' GSM981249_hg19_wgEncodeCshlLongRnaS
eqImr90CellPapGeneGencV10.txt'
GSM981250' SKPNPSH' nucleus' GSM981250_hg19_wgEncodeCshlLongRnaS
eqSknshNucleusPapGeneGencV10.txt'
GSM981251' SKPNPSH' cytosol' GSM981251_hg19_wgEncodeCshlLongRnaS
eqSknshCytosolPapGeneGencV10.txt'
GSM981252' MCFP7' cytosol' GSM981252_hg19_wgEncodeCshlLongRnaS
eqMcf7CytosolPapGeneGencV10.txt'






high' confidence' set)' and' RefSeq' (NM_*' records' only)' respectively.' Using' Perl'
scripting,' all' canonical' open' reading' frames' (ORF)' are' determined' both' in' the'
transcript' sequence'and' in' the' reverse' complement.' Further' analysis' is' performed'
using' the' statistical' environment' R' and' the' ggplot2' and' dplyr' packages.' For' each'
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DEVELOPMENT* OF* COMBINED* MRNA* AND* LNCRNA*
EXPRESSION*PROFILING*PLATFORMS*
PIETER&JAN* VOLDERS,* PIETER* MESTDAGH,* BJÖRN* MENTEN* &* JO*
VANDESOMPELE*
INTRODUCTION'
Long' non3coding' RNA' (lncRNA)' constitute' a' large' and' diverse' class' of' non3coding'
RNA' genes.' Although' several' lncRNAs' have' been' functionally' annotated,' the'
majority' remains' to' be' characterized.' LNCipedia' (http://www.lncipedia.org)' is' the'
largest'public' compendium'of' lncRNAs'with'and'without'a'known' function1.'While'
microarrays' are' a' popular' choice' for' gene' expression' profiling' studies,' the'
commercial' platforms' lack' probes' covering' lncRNAs.' Hereby' we' describe' the'
development' of' several' custom' gene' expression' platforms' for' detection' of' both'
mRNA'and'lncRNA'expression'using'Agilent'SurePrint'technology.'
EXPRESSION'ARRAY'VERSION'1'(MARCH'2012)'
The' SurePrint' G3' Human' Gene' Expression' Microarrays' offered' by' Agilent'
Technologies' are' a' popular' choice' for' gene' expression' profiling' studies' both' in'






the' poorly' annotated' lncRNAs' from' the' commercial' platform' and' reducing' the'
number'of'replicate'probes,'we'were'able'to'free'enough'space'to'fit'all'the'content'
RESULTS' 104'
on' the' 8x60k' platform.' Using' Agilent’s' eArray' applicationa,' we' designed' 23,042'
lncRNA' specific' probes' covering' 96%' of' all' LNCipedia' transcripts' available' at' the'
time.' The' final'microarray' design' consists' of' the' Agilent'mRNA' probe' groups,' the'






Currently,' a' total' of' 1134'hybridizations'have'been'performed'at' the'CMGG'using'
this' design' as' part' of' experiments' belonging' to'many'different' research'units' and'




With' the' release' of' LNCipedia' version' 2.14' mid' 2013' we' revisited' the' expression'
array' design.' Given' the' substantial' increase' in' lncRNA' content,' only' 75%' of' the'
lncRNA'genes'in'LNCipedia'2.1'were'covered'by'the'initial'version'of'the'expression'
array.' We' therefore' set' out' to' update' the' design' and' create' a' second' gene'
expression'profiling'platform.'As'we'again'opted'for'the'8x60k'layout,'we'could'not'
cover'every' lncRNA'transcript'with'a'unique'probe,'as' the'number'of'spots'on'the'
array' is' insufficient.' To' cover' all' possible' lncRNAs' in' LNCipedia' nonetheless,' we'
opted'to'select'probes'in'overlapping'exons'and'thus'minimize'the'number'of'probes'
required.'Our'algorithm'preferentially'selects'probes'that'target'the'highest'number'
of' transcripts' in' a' certain' locus.' Using' this' strategy,' we' selected' 25' 961' probes'











the'UGent' spin3off' company'Biogazelle'which' has' currently' used' it' to' profile' over'
350'samples.'
COLLABORATION' WITH' AGILENT' TECHNOLOGIES' AND'
DEVELOPMENT'OF'A'COMMERCIAL'PLATFORM'
Following' the' success' of' the' custom'microarray,'we' contacted'Agilent' to' evaluate'
the' commercial' potential' of' our' design.' After' positive' evaluation' by' Agilent,' the'
company'decided'to'use'this'design'as'a'basis'for'the'development'the'next'version'
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A* (Universal*human*reference*RNA,*Agilent*Technologies),*B* (Human*brain* total*RNA,*Ambion),*C*
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TARGETED! GENOMIC! SCREEN! REVEALS! FOCAL!





The! landscape! of! somatic! copy4number! alterations! (SCNAs)! affecting! long! non4
coding! RNAs! (lncRNAs)! in! human! cancer! remains! largely! unexplored.! While! the!
majority! of! lncRNAs! remains! to! be! functionally! characterized,! several! have! been!






affecting! neighboring! protein4coding! genes.! These! focal! aberrations! are! highly!
suggestive!for!a!tumor!suppressive!or!oncogenic!role!of! the!targeted! lncRNA!gene.!
Although! functional! validation! remains! an! essential! step! in! the! further!
characterization! of! the! involved! candidate! cancer! lncRNAs,! our! results! provide! a!
direct!way!of!prioritizing!candidate!lncRNAs!involved!in!cancer!pathogenesis.!
INTRODUCTION!
The! cancer! genome! is! marked! by! large! numbers! of! genetic! and! non4genetic!
alterations.!The!greater!majority!of! those!are!somatic.!Only!a! small! fraction!of! the!
somatic! mutations,! the! so4called! driver! mutations,! contribute! to! cancer!
development!by!activating!or! inactivating!specific!cancer!genes.!The!remainder!are!
passenger! mutations! that! do! not! confer! growth! advantage! but! were! acquired! at!
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some! point! during! cancer! cell! proliferation1.! Differentiating! between! driver! and!
passenger!mutations!is!of!the!biggest!challenges!in!the!quest!for!new!cancer!genes!
and! putative! therapeutic! targets.! While! somatic! alterations! can! be! as! small! as! a!
single! nucleotide! substitution,! insertion! or! deletion,! somatic! copy4number!
alterations! (SCNA)!affect! the! largest! fraction!of! the!genome2.! In! some!cases,!SCNA!
affect! entire! or! partial! chromosome! arms.! The! ability! to! detect! these! genetic!
alterations!using!(molecular)!cytogenetic!methods!has!made!large!SCNA!historically!
the!best!studied!cancer!associated!genetic!alterations.!Many!well4known!oncogenes!
and! tumor! suppressor! genes! have! been! initially! identified! as! targets! of! recurrent!
genomic! amplifications! or! deletions,! respectively.! Notable! examples! are! tumor!
suppressor! genes! PTEN3! and! RB14! and! oncogenes! HER2! (ERBB2)5! ! and! the! MYC4
family!of!transcription!factors6,7.!The!resulting!diagnostic!and!therapeutic!successes!
have! made! cancer! SCNA! subject! of! many! studies.! Additionally,! the! advent! of!
genome4wide! array! comparative! genome! hybridization! (array4CGH)! platforms! that!
enable!robust! identification!of!small!SCNAs!greatly! improved!our!knowledge!of!the!
cancer!genome8410.!
As! cancer!genetics!until!now!mainly! focused!on!protein4coding!genes,!not!much! is!
known! on! SCNAs! affecting! non4coding! RNA! genes! in! cancer.! In! recent! years,! our!
knowledge!on!the!non4coding!genome!has!expanded!enormously.!This! is!especially!
the!case! for! the!class!of! long!non4coding!RNAs! (lncRNAs),! consisting!of!genes!with!
transcripts! larger! than! 200! nucleotides! that! do! not! encode!proteins.! In! the! past! 5!
years,!ten!thousands!of!human!lncRNAs!have!been!reported!and!catalogued,!making!
this! the! largest! genetic! class! in! the! human! genome11.! While! the! bulk! of! lncRNAs!
remains!to!be!functionally!annotated,!they!have!been!implicated!in!many!important!
normal!cellular!processes!such!as!dosage!compensation12,!chromatin!remodeling13,!




hiatus! in! our! knowledge! on! lncRNA! SCNAs! is! the! fact! that! the!majority! of! lncRNA!
annotations! are! very! recent.!Most! commercially! available! platforms! are! based! on!
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older! genomic! annotations! (with! no! probes! for! lncRNAs,! or! probes! for! as! yet!
unannotated! lncRNAs)! or! lncRNAs! are! simply! overlooked! in! the! data! analysis.!
Indeed,! recurrent! SCNAs!outside!of!protein! coding! regions!have!been! reported2,19.!
To!overcome!this!problem,!existing!DNA!microarray!platforms!have!been!repurposed!
and!probe!content!was!reannotated!with!current! lncRNA!annotation20,21.!One!such!
effort! resulted! in!the!discovery!of! the!oncogenic!FAL1!(focally!amplified! lncRNA!on!
chromosome!1)!lncRNA!in!ovarian!cancer21.!While!the!potential!of!this!approach!lies!
in!its!ability!to!make!use!of!the!large!amount!of!publically!available!DNA!microarray!
data,! the! used! platforms! have! several! disadvantages! for! the! discovery! of! putative!
cancer! associated! lncRNAs.!Whole! cancer! genome! sequencing!has! the!potential! in!
principle!to!circumvent!these!limitations,!but!the!method!is!still!relatively!expensive,!
and! challenging! in! terms! of! data4analysis.! Consequently,! public! databases! (e.g.!
TCGA)! are! mainly! populated! with! targeted! exome! sequencing! datasets,! again!
focusing!on!protein!coding!genes.!
The! occurrence! of! SCNAs! is! inversely! proportional! to! their! size,! with! small! SCNAs!
being!more! common! than! larger! ones2,19.!However,! smaller! SNCAs! are! covered!by!
fewer! probes! making! them! more! difficult! to! detect! reliably.! It! is! reasonable! to!
assume! that! a! substantial! number! of! SCNAs! are! overlooked! in! this! way.! As! SCNA!
recurrence! is! often!used! to!prioritize! putative! cancer! genes,!more! samples!will! be!
required! to! compensate! for! the! undetected! small! SCNAs.! Secondly,! reliably!
detectable! and! thus! larger! SCNAs! will! contain! multiple! genes,! possible! including!
protein4coding!genes,!making!it!harder!to!identify!lncRNA!cancer!genes.!
Here! we! present! a! targeted! and! cost4effective! approach! to! identify! focal! lncRNA!
SCNA!based! on! a! custom!DNA!microarray! covering! 20! 418! lncRNA! transcripts! and!
their! flanking!protein!coding!genes.!We!show!the!ability!of! this!platform!to!detect!
focal! aberrations! that! only! affect! lncRNA! exons! and! not! encompass! their! flanking!
protein!coding!genes.!By!analyzing!the!DNA!of!80!cancer!cell!lines!covering!11!cancer!
subtypes! we! reveal! that! lncRNAs! are! frequently! targeted! by! focal! aberrations! in!





LncRNA! transcript! annotation! was! obtained! from! LNCipedia22! (version! 1.0)! and!
stored! in! a! MongoDB! NoSQL! database.! Protein! coding! transcript! annotation! was!
obtained!from!Ensembl’s23!biomart!(version!64,!September!2011)!and!stored!in!the!
same! format.! For! every! lncRNA! transcript,! the! nearest! upstream! and! downstream!
protein!coding!transcript!was!determined.!To! interface!with!the!MongoDB!dataset,!
both! perl! scripts! and! mongo! shell! scripts! were! employed.! Using! MongoDB’s!




A!BED! file!of! all! non4redundant!exons!was!generated! from! the!exon!database!and!
uploaded!into!eArray!for!probe!design.!Since!our!criterion!to!have!2!probes!per!exon!
was! initially! not!met,! the! exon! boundaries! were! extended! and! the! corresponding!
BED!files!were!uploaded!as!well.!Exon!boundaries!are!extended!with!100!bp,!300!bp!
and!500!bp.!In!addition,!less!stringent!selection!parameters!were!used!for!the!500!bp!
extended! exon.! In! this! way,! 5! probe! datasets! were! generated! and! stored! in! a!
separate! MongoDB! collection.! From! this! collection,! 2! probes! per! exon!
(neighborhood)!were! selected!with!preference! for! the!probes! closest! to! the! exon.!
Overlapping!transcripts!were!taken!into!account!to!avoid!duplicate!probe!selection.!
For! transcripts!with! fewer! than!5!exons,! additional! probes!were! selected!until! the!
transcript!was!covered!by!at!least!10!probes.!For!the!flanking!protein!coding!genes,!
probes!were! designed! for! the! 2! exons! closest! to! the! lncRNA.! From! this! set,! the! 2!
probes! nearest! to! the! lncRNA!were! selected.! The! resulting! set! of! 166! 417! unique!
probes!was!uploaded!to!eArray!and!supplemented!with!normalization!and!QC!probe!







in! the!NCI! 60! cancer! cell! line! panel.! The! neuroblastoma! and! T4ALL! cell! lines!were!




Bioprime! array! CGH! genomic! labeling! system! (Invitrogen,! Belgium).! In! parallel,!
Kreatech! gender4matched! controls! were! labeled! with! Cy54dCTP.! Samples! were!








used! to! combine! the! segment! annotation! with! lncRNA! and! protein! coding! gene!
annotation! in! other! collections! and! implement! the! filtering! process.! First,! only!
segments!that!overlap!lncRNA!exons!are!retained.!Next,!segments!with!an!absolute!
average! log4ratio! less! than! 1.5! are! discarded! as! are! segments! contained! within!
segmental! duplications! (UCSC! genomicSuperDups! track)! or! segments! that! overlap!
with!more!than!3!known!variants!(database!of!genomic!variants25).!The!absolute!log4
ratio!of!the!nearest!segments!covering!the!flanking!protein!coding!genes!should!be!





QPCR! assays! are! designed! based! on! the! chromosomal! locations! of! the! altered!
segment! covering! the! lncRNA! and! the! nearest! exons! of! the! two! flanking! protein!
coding! genes.! Primer! design! is! performed! using! Primer326,! primers! spanning!
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Calculation! of! normalized! relative! quantities! was! done! using! the! qbase+! software!
version! 2.6! (Biogazelle)! and! the! open! source! statistical! environment! R! (version! 3).!
The! Cq! values! corresponding! to! the! altered! segment! are! normalized! to! those!
corresponding!to!the!flanking!protein!coding!genes!and!scaled!to!the!control!sample!




LncRNAs!are!underrepresented!on! commercial! array!CGH!platforms!and! the!mean!
chromosomal!distance!between!the!probes!on!these!arrays!makes!them!unsuitable!








sequence! of! the! lncRNA! exons! and! the! two! nearest! exons! of! the! flanking! protein!
coding! genes.! By! removing! duplicate! probes! in! overlapping! exons! and! selecting!
additional! probes! for! transcripts! with! fewer! exons,! we! were! able! to! cover! the!






CGH! platforms.! The! average! log! ratio! in! 1!Mb! bins!was! calculated! and! correlated!
between! the! different! platforms.! These! correlations! were! compared! with!
correlations! among! unrelated! cell! lines! (Figure! S5! and! Figure! S6).! Correlation!
between!the!same!cell! lines!across!different!platforms!was!high!(median!Pearson’s!
correlation! =! 0.70),! validating! the! quality! of! our! profiles.! As! expected,! cell! lines!
derived!from!the!same!individual!(such!as!NCI/ADR4RES!and!OVCAR48)!are!also!highly!
correlated!(Pearson’s!correlation!=!0.74).!In!addition,!this!analysis!revealed!problems!
with! 2! DNA! samples! (HCT415! and! CAKI41)! as! the! obtained! profiles! showed! poor!






filtering! was! performed! on! the! resulting! segments! to! shortlist! focal! lncRNA! SCNA!




the! case! of! a! copy! number! gain,! an! additional! requirement!was! that! the! segment!
includes! the! entire! transcript.! Finally,! to! withhold! a! focal! SCNA! (5),! the! segment!
cannot! overlap! any! of! the! flanking! protein! coding! gene! exons.! To! attribute! for!
anomalies! in! the! circular! binary! segmentation! process! that! generates! multiple!
segments! for! the! same! genetic! alteration,! we! pose! further! requirements! on! the!
segments! spanning! the! flanking! protein! coding! genes.! A! SCNA! is! only! considered!




line!were! identified! (Figure!2).!The!majority!of! these! lncRNAs! (111)! is!affected! in!a!
single!cell!line,!16!are!affected!in!2!cell!lines,!7!in!3!cell!lines,!1!in!4!cell!lines!and!1!in!
5! cell! lines.! By! confining! the! relative! difference! in! log4ratio! between! the! segment!
covering!the!lncRNA!and!the!segment!covering!the!flanking!protein!coding!genes,!it!









in! copy! number! between! the! two.! Using! this! strategy,! we! evaluated! 88! events!
(Figure!3).!For!66!of!these!(75%)!an!altered!copy!number!status!compared!to!at!least!
one!of! the! two! flanking!assays!could!be!confirmed,!of!which!43! (49%)!showed!the!
expected! relative! difference! in! Cq! values!with! both! flanking! assays! and!were! thus!
validated! as! focal! aberrations.! The! validation! rate! is! higher! for! the! amplifications!
than! for! the! deletions! (56%! and! 48%,! respectively).! The! validation! rate! drastically!
increases! when!we! limit! our! analysis! to! the! subset! of! segments! with! an! absolute!
average! log4ratio! larger! than! 2.5.! In! that! case,! 58! out! of! 64! (91%)! events! are!
confirmed! copy! number! alterations.! The! fraction! of! confirmed! focal! aberrations!
remains!similar!(53%).!
MOST! NOVEL! LNCRNA! ABBERATIONS! DO! NOT! CORRESPOND! TO! COMMON! SOMATIC!
VARIANTS!
As!our!custom!platform!differs!considerably!from!other!array!CGH!platforms,!it!not!
unlikely! that! the! newly! found! SCNAs! actually! comprise! uncharted! germline! copy4
number! variants! that! may! exist! in! a! normal! population! and! do! not! contribute! to!
cancer.! To! assess! this! possibility,! we! performed! an! RT4qPCR! experiment! for! five!
validated! loci!on!DNA! from!192!healthy! individuals.!Neither!homozygous!deletions!
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nor!high!order!amplifications!could!be!detected!for!any!lncRNA!in!any!of!the!samples!




cell! lines,! we!were! able! to! detect! a! large! number! of! SCNA! that! specifically! affect!
lncRNA! exons.! This! suggests! that! similarly! to! protein4coding! genes,! lncRNAs! are!
frequently! targeted! by! SCNAs! in! cancer.! After! rigorous! filtering! focused! on! novel!
highly!aberrant!segments!that!not!encompass!protein!coding!genes,!we!report!136!
such! events,! including! 25! that! are! recurrent.!Of! those,! 76! events!were!marked! as!
focal! based! on! the! copy! number! of! the! flanking! protein! coding! genes.! Since! the!
cancer!genome!harbors!many!large!SCNAs,!it!is!important!to!also!consider!the!events!




Figure! S3).! PVT1! has! been! implicated! in! several! cancer! types! including! gastric!
cancer28,!ovarian!cancer!and!breast!cancer18.!PVT1!copy!number!was!found!to!be!co4
gained!in!more!than!98%!of!cancers!with!a!MYC!copy!number!increase29.!Our!work!
not! only! confirms! frequent! amplification! of! PVT1! in! cancer,! but! also! reveals! that!
PVT1! amplifications! can! be! focal.! Another! interesting! accordance! with! previous!
studies!is!found!in!a!large4scale!pan4cancer!study!on!SCNAs19.!Although!the!authors!
mainly! focus! on! SCNAs! affecting! protein! coding! genes! and! use! limited! lncRNA!
annotation,!they!report!one!lncRNA,!lnc4DCTD45!(LINC00290),!as!the!sole!member!of!
a! frequently! deleted! region.! Our! results! reveal! a! recurrent! and! focal! deletion! in!
ovarian!and!breast!cancer!cell!lines,!suggesting!a!role!in!cancer!(Figure!2).!!
The!validation!rate!determined!with!qPCR!was!strongly!dependent!on!the! log4ratio!
cutoff! applied! to! the! segments,!with! an! absolute! average! log4ratio! larger! than! 2.5!
showing! high! validation! rates! for! lncRNA! copy! number! status.! The! relatively! high!
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cutoff!is!likely!to!be!related!to!the!unique!design!of!our!platform.!As!the!probes!are!
confined! to! small! genomic! loci! (lncRNA! exons)! is! it! not! unimaginable! that! the!












and! focal! lncRNA! SCNAs.! We! have! screened! a! panel! of! 80! cancer! cell! lines! and!
shortlisted! 136! lncRNA! genes! with! a! putative! role! in! cancer.! Among! this! list! are!
several!lncRNAs!that!have!been!implicated!in!cancer,!validating!our!approach.!Since!
the! great! majority! of! the! lncRNAs! on! our! platform! have! yet! to! be! functionally!
studied,! this! finding! suggests! that!our! research!provides!many!new! cancer! related!
lncRNA!genes.!We!present!a!set!of!lncRNA!genes!to!the!lncRNA!and!cancer!research!


















































































cancer1subtype1 #1 cell1lines1 origin1
breast! 6! MCF7,!MDA4MB4231,!HS578T,!BT4549,!T47D,!MDA4MB4468! NCI!
CNS! 6! SF4268,!SF4295,!SF4539,!SNB419,!SNB475,!U251! NCI!
colon! 7! COLO205,!HCC42998,!HCT4116,!HCT415,!HT29,!KM12,!SW4620! NCI!






non4small!cell!lung! 9! A549,!EKVX,!HOP462,!HOP492,!NCI4H226,!NCI4H23,!NCI4H322M,!NCI4H460,!NCI4H522! NCI!
ovarian! 7! IGROV1,!OVCAR43,!OVCAR44,!OVCAR45,!OVCAR48,!SK4OV43,!NCI4ADR4RES! NCI!
prostate! 2! PC43,!DU4145! NCI!
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coding' RNAs' (lncRNAs)' is' evaluated.' Several' features' of' both' the' oligo' and' the' target' RNA' are'




accuracy' in' predicting' functional' ASOs.' In' addition,' the' effect' of' two' nucleic' acid' analogs' (2’LOL
methyl'and'locked'nucleic'acid)'is'evaluated.'The'use'of'nucleic'acid'analogs'decreases'the'required'
dose' and' increases' the' stability' of' the' knockdown' over' time.' Furthermore,' the' design' and'
evaluation'of'nonLtargeting'controls'oligos'is'discussed.'Together,'this'research'shows'that'ASOs'can'





of' this' transcription' and' have' given' rise' to' a' new' group' of' RNAs' termed' long' nonLcoding' RNAs'
(lncRNAs)1L3.'Although'the'function'of'various'lncRNAs'has'been'studied'in'detail,'the'great'majority'
remains'to'be'fully'characterized4.'
Perturbation' of' gene' expression' is' an' important' aspect' of' functional' genomics' research' and'
antisenseLbased' tools' have' proven' to' be' valuable' for' this' purpose.' From' the' lab,'where' they' are'
used' to' study' the' function' of' the' target' gene,' they' are' finding' their' way' to' the' clinic,' where'
overexpression' of' disease' associated' genes' is' attenuated' by' administration' of' antisense' drugs5.'
Oligonucleotides'with'sequence'complementarity'to'a'known'target'can'inhibit'the'function'of'the'
RESULTS' 140'
target' via' three' mechanisms:' RNA' interference' (RNAi),' ribonuclease' H' (RNase' H)' mediated'
degradation'and'steric'hindrance6.'
RNase'H'is'an'endonuclease'that'specifically'cleaves'DNA/RNA'duplexes'and'can'be'trigged'by'small'






most' popular' and' readily' available' modification' of' the' backbone' is' the' replacement' of' the'
phosphodiester' bond'with' a' phosphorothioate' (PS)' linkage.' Full' PSLDNA'oligos' show'an' improved'
nuclease'resistance,'while'retaining'the'ability'to'induce'RNase'H'mediated'cleavage8.'A'broad'range'
of'sugar'modifications'has'been'developed'and'many'have'been'shown'to'improve'the'efficacy'and'
stability' of' ASOs7,9.' Commonly' used' sugar' modifications' include' 2’LOLMethyl' (2'OMe),' 2’LOL
Methoxyethyl'(2'MOE)'and'locked'nucleic'acid'(LNA)10.'Many'of'these'sugar'modifications9'are'often'
used' in'chimeric'gapmer'conformations'where' two'regions'consisting'of'modified' residues' flank'a'
central'part'of'unmodified'nucleotides.'Gapmers'have'an' improved'affinity'and'stability'compared'
to' PSLDNA' backbone' oligos' without' inhibiting' RNase' H' cleavage9.' Although' RNase' H' activity' is'
generally'desirable,' in' some'cases'better' results'are'achieved'when' fully'modified'oligos'are'used'
instead.' These' molecules' will' provide' steric' hindrance' and' prevent' interaction' with' other'
macromolecules'or'prevent'correct'processing'of'the'primary'RNA'transcript.'
Antisense' strategies' that' show'great' effectiveness' to' silence'or' functionally' impair' proteinLcoding'
genes'may' be' unsuitable' for' lncRNAs.'While' oligos' that' interfere'with' ribosome' binding' are' very'
powerful'for'mRNA'silencing11,'they'have'poor'potential'for'use'against'lncRNAs'as'lncRNAs'are'by'
definition' not' translated' to' protein.' Furthermore,' the' great' majority' of' lncRNAs' are' nuclear'
retained12'and'many'have'described'functions'in'the'nucleus13,14.'This'requires'oligonucleotides'that'
can'efficiently'pass'the'nuclear'membrane'and'trigger'a'nuclease'that'functions'in'the'nucleus.'
Until' now,' researchers' have' predominantly' used' small' interfering' RNAs' to' achieve' transient'




siRNAs' and' improves' delivery' to' the' nucleus,' where' the' great'majority' of' lncRNAs' is' found17.' In'
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contrast'to'siRNAs,'ASOs'can'mediate'knockdown'when'targeted'to'intronic'sequences'as'well18.'As'
lncRNAs'are'not' translated'and'the'mature'RNA'transcript' is'also'the' functional' form'of' the'gene;'
intronic' ASOs' prevent' formation' of' the' functional' transcript' and' as' such' improve' the' chances' of'
observing' a' phenotype.' The' lack' of' a' second' strand' has' other' advantages' as'well,' for' instance' it'
reduces'the'risk'of'offLtarget'effects17.''
Successful'application'of'ASOs'in'vivo'in'the'lncRNA'research'field'has'been'reported.'For'instance,'













Following' trypsinization' and' dilution,' HEKL293T' cells' were' cultured' in' 96Lwell' plates' at' 10' 000'
cells/well'density'(90'µl).'Transfection'with'DharmaFECT'2'(Dharmacon)'is'performed'24'hours'after'
seeding.'10'µl'of' transfection'solution' is'added'resulting' in'a' final'DharmaFECT'2'concentration'of'
4%' and' ASO' concentration' of' 100' nM.' Control' samples' are' treated' with' transfection' solution'
without'ASO'(reagent'only)'or'not'treated'at'all'(cells'only).'
SKLMELL28'cells'are'cultured' in'100'µl' (10'000'cells/well)' and'are' transfected'using'Lipofectamine'
(Life' Technologies).' 50' µl' transfection' solution' is' supplemented' after' 24' hours' so' that' the'
Lipofectimine'concentration'is'1.7%'and'the'ASO'concentration'100'nM.'
Cell'lysis'and'RNA'extraction'is'performed'using'the'SingleShot'SYBR'Green'Kit'(BioLRad)'according'to'
the'manufacturer’s' instructions.' In' brief,' cells' were' washed' with' 125' μl' of' Ca2+L' and'Mg2+Lfree'

















neighbor' parameter' sets' are' being' used:' SantaLucia' et' al.' 200420' for' DNA/DNA' hybridization,'
Sugimoto'et'al'199521'for'DNA/RNA'hybridization'and'Owczarzy'et'al'201122'LNA/DNA'hybridization.'
To'assess'the'accessibility'of'the'target'RNA,'the'RNAplfold'program'from'the'ViennaRNA'package'






short' read' aligner' bowtie' (version' 0.12.7).' The' used' reference' genomes' are' hg19' (GRCh37)' for'
human'and'mm10'(GRCm38)'for'mouse.'Only'alignments'without'mismatches'are'considered,'oligos'





chosen.'All' calculations'are'performed' in'R' (version'3.1.2)'and' the'package'mgcv' (version'1.8).'To'
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assess'if'a'model'with'a'certain'parameter'set'improves'over'a'model'with'a'different'parameter'set,'
the' anova.gam' function' in' the'mgcv' package' is' used.' The' quality' of' the' predictions' is' evaluated'
using'crossLvalidation'and'the'ROCR'package'(version'1.0).''
NONLTARGETING'CONTROLS'
NonLtargeting' controls' (NTC)' are' designed' by' permuting' the' sequence' of' functional' oligos' until' a'
sequence' is' obtained'with' no' perfect' homology' to' the' reference' genome.'NTC' sequences' should'
have'at'least'2'mismatch'nucleotide'compared'to'the'genome'sequence.'
CELL'VIABILITY''
Cell' viability' is' evaluated' using' the' CellTiterLGlo' luminescent' cell' viability' assay' available' from'
Promega.' Cells' are' cultured' in' 96Lwell' plates' as' described' before.' 48' hours' after' transfection,'




house' developed' gene' expression' array' based' on' the' Agilent' SurePrint' platform.' This' array'
measures'both'lncRNA'and'mRNA'expression.'The'mRNA'probe'content'is'based'on'the'SurePrint'G3'
Human' Gene' Expression' 8x60K' v2' Microarray' while' the' probes' for' lncRNA' are' designed' using'







To'assess' the'potential'of'PSLmodified'ASOs' for'knockdown'of' lncRNA'transcripts'and' to'generate'
empirical' data' for' modeling' (see' further),' a' screening' experiment' was' performed.'We' randomly'
selected'90'specific'16Lmers'covering'6'lncRNA'genes.'Oligonucleotides'with'multiple'occurrences'in'
the' reference' genome' and' as' such' possible' offLtarget' effects' were' rejected.' Target' lncRNA'
expression' was' measured' with' RTLqPCR' in' the' treated' samples' and' compared' to' nonLtargeting'
control'oligos,'untreated'cells'and'cells'treated'with'transfection'reagent'only.'Although'the'success'
rate' differs' between' the' different' transcripts,' knockdown' >' 50%' is' observed' with' at' least' some'
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from' the' screening' experiment' for' modeling.' Thermodynamic' properties' of' the' oligo' –' target'
interaction' have' been' established' as' powerful' predictors' of' oligo' performance23.' Therefore,' the'
significance'of' the'Gibbs' free'energy' (∆G)'of'oligo'–' target'annealing,'oligo'dimerization'and'oligo'
selfLinteraction' was' assessed' using' generalized' additive' modeling' (GAM),' a' nonLparametric'
expansion' of' generalized' linear' modeling' (GLM).' GAM' confirmed' that' the' ∆G' of' oligo' –' target'
annealing' and' the' ∆G' oligo' dimerization' are' significant' predictors' for' the' observed' knockdown'
(Figure'2).'Oligo'selfLinteraction'was'the'only'nonLsignificant'parameter'and'was'therefore'excluded'
from' further'analyses.'Next,'different'versions'of' the'parameters'were' tested' to' see' if' they'could'
improve' the'model.' For' the'∆G'of' oligo' –' target' annealing,' two' nearest' neighbor' parameter' sets'
were' compared.' The'parameter' set' from'SantaLucia' et' al.' 200420' for'DNA/DNA'hybridization'was'




the' importance'of' the' secondary' structure'of' the' target' site'has'been'documented24.'The' in* silico'
assessment'of'RNA'structure' is'not'a' trivial' task,'and'the'best' results' for' large'RNA'fragments'are'
obtained'when'the'prediction'is'limited'to'small'regions25.'The'RNAplfold'algorithm26'computes'the'
probability'that'a'chosen'region'is'free'from'base'pairing'and'hence'available'for'ASO'binding.'This'





positive' interactions' on' large' stretches' of' RNA' and' using' a' sliding' window' approach' is'
recommended25.'To'further' improve'the'predictive'value,'the'accessibility' is'averaged'over'several'
bases.' The' third' parameter' that' was' optimized' determines' the' size' of' the' window' in' which' the'




Of' the' 90' tested' PSLASOs,' 35' target' an' intron' of' the' transcript.' The' effect' of' the' ASO' position'
(intronic'vs.'exonic)' is'not'found'to'be'a'significant'predictor' in'this'analysis.'Several' intronic'ASOs'









Natural' single' stranded'DNA'molecules' are' rapidly'degraded'by'nucleases'and'as' such' show'poor'
stability' and' knockdown' efficacy.' These' features' can' be' improved' dramatically' through' specific'
modifications' of' the' DNA' structure8.' Currently' a' wide' range' of' modifications' is' being' used' in'
research' and' clinical' applications.' In' this' study,' the' potency' of' two' popular' sugar' modifications,'
namely' 2’LOLmethylation' (2’LOLme)' and' locked'nucleic' acids' (LNA),'were' evaluated.' In' the' chosen'
gapmer'configuration,'the'first'3'and'last'3'nucleic'acids'are'substituted'with'2’LOLme'or'LNA'nucleic'
acid'analogs'(3L10L3'conformation).'Four'PSLDNA'ASOs'were'selected'and'tested'alongside'their'2’L
OLme'and'LNA'gapmers.'Using' two'different'concentrations' (10'nM'and'100'nM),' the'knockdown'
was'measured'at'5' time'points' (12,'24,'48,'72'and'96'h'postLtransfection).'Although'there' is' little'
difference'in'the'measured'knockdown'at'the'early'time'point'(24'h)'using'a'100'nM'concentration,'
it' is' clear' that' the'use'of'nucleic' acid' analogs'has' a' great' impact'on' the' knockdown'at' later' time'
points' and' lower' concentrations' (Figure' 3,' S4).'While' the' effect' of' pure' PSLDNA' oligos' decreases'
over'time,'LNA'gapmer'mediated'knockdown'remains'stable'over'the'course'of'the'experiment.'In'
addition,' it' is' apparent' that,' especially' for' the' LNA' gapmers,' even' at' the' 10' nM' concentration,'
substantial'knockdown'is'observed.'This'either'suggests'a'higher'affinity'of'the'ASO'to'the'RNA'or'
improved' activation' of' RNase'H.' Indeed,' an' improved' affinity' has' already' been' reported' for' LNA'




This' is' a' considerable' difference' when' taking' into' account' the' ∆G' range' required' for' efficient'





targeting' controls' are' indispensable' to'evaluate' the' true'effect'of'a' targeting'oligo.'NonLtargeting'
oligos'are'developed'by'random'permutation'of'the'sequence'of'functional'oligos'until'a'sequence'is'
obtained'with'no'homology' to' the' reference'genome.'Three'different'NTCs'were'designed' in' this'




S6).' To' elucidate' the' sequence' independent' effects' related' to' the' chemistry,' PSLDNA' NTCs'were'





ASO' transfection' has' impact' on' cell' viability,' CellTiterLGlo' luminescence' was' measured' 48h' post'
transfection.'Two'different'cell' lines'were'transfected'with'the'NTCs'described'earlier' to'elucidate'
the' sequence' independent' effects.' In' addition,' two'different' transfection' reagents'were' tested' in'
parallel.'Both'transfection'reagents'reduce'the'cell'viability'of'the'two'cell'lines,'although'SKLMELL28'
seems' more' resistant' to' this' toxicity' than' HEKL293' (Figure' 4).' In' HEKL293,' a' more' pronounced'
reduction' in' viability' is' observed' when' both' transfection' reagent' and' ASO' are' present.' This'
increased'toxicity'is'observed'for'all'tested'ASOs'and'is'thus'sequence'and'chemistry'independent.'
The'additional'reduction'in'viability'cannot'be'observed'in'the'SKLMELL28'cell'line.'Repetition'of'this'
experiment' confirmed' these' findings.' Together,' these' results' show' the' importance' of' validated'
NTCs'when'ASOs'are'used'in'phenotyping'experiments.'
CONCLUSIONS'
ASO'are' successfully'applied' to' reduce' the' intracellular'RNA'concentration'of' their' target' lncRNA.'
Random'selection'of'ASOs'with'perfect' complementarity' to'a' lncRNA' target'of' interest' is' a' viable'
option' for' ASO' selection' although' the' success' rate' is' low;' only' few' random' ASOs' show' a' good'
knockdown'performance.'Upfront'selection'of'functional'ASOs'with'high'potential'should'reduce'the'










and' tested.' In' conclusion,' this' work' provides' lncRNA' research' community' with' several' tools' and'
strategies'that'empower'them'to'apply'ASOs'for'the'knockdown'of'their'lncRNA'of'interest.'
AVAILABILITY'
A'webLinterface' has' been' developed' that' allows' users' to' design' ASOs' for' an' RNA' of' interest.' All'
potential' ASOs' are' evaluated' using' the' described' GAM'model.' In' addition,' nonLspecific' ASOs' are'





































































with! transfection! reagent! only.! Mean! knockdown! is! plotted! along! with! the! standard! error!














Figure! 3:! Different! nucleic! acid! analogs! increase! ASO! potency! and! stability.! The! same!
oligonucleotide! sequence! yields! different! results! when! different! modifications! are! being! used.!
Although! the! differences! are! subtle! for! the! 100! nM! concentration! (left)! compared! to! the! 10! nM!





Figure!4:! CellTiter@Glo! luminescence! relative! to! the!non@treated! sample!as! a!measure! for! relative!





























Figure! S6:! Volcano! plot! showing! the! expression! of!mRNAs! and! lncRNAs!measured! by! expression!





ID# target# sequence# chromosome# position#ENST_62_1) lnc-SYNPR-2:3) CCGTCCTGGGACAGCC) chr3) 62974917)ENST_62_2) lnc-SYNPR-2:3) ATTTCCGTGTGGCTGA) chr3) 62936177)ENST_62_3) lnc-SYNPR-2:3) GTGTCTGGGAGCCAAC) chr3) 62939395)ENST_62_4) lnc-SYNPR-2:3) CGTCCTGGGACAGCCA) chr3) 62974916)ENST_62_5) lnc-SYNPR-2:3) TGTCTGGGAGCCAACA) chr3) 62939394)ENST_62_6) lnc-SYNPR-2:3) AGCAGATTCACTGGGC) chr3) 62970735)ENST_62_7) lnc-SYNPR-2:3) GCCAGAAGGTCCTCAG) chr3) 63099348)ENST_62_8) lnc-SYNPR-2:3) TACAAGAAGATACAAT) chr3) 62974866)ENST_62_9) lnc-SYNPR-2:3) CTCTTATGCCTATAAG) chr3) 62937682)ENST_62_10) lnc-SYNPR-2:3) ATTATATAAGAATCTC) chr3) 63060671)ENST_25_1) lnc-GLT1D1-1:9) GGGCGCCGGATGCCCA) chr12) 129596076)ENST_25_2) lnc-GLT1D1-1:9) GCGCCGGATGCCCACC) chr12) 129596074)ENST_25_3) lnc-GLT1D1-1:9) GGCAGGGGGGCTGCAT) chr12) 129595561)ENST_25_4) lnc-GLT1D1-1:9) GCTGAGGGCAGCGACG) chr12) 129595539)ENST_25_5) lnc-GLT1D1-1:9) GGTCTCCCTCCGAGCA) chr12) 129595628)ENST_25_6) lnc-GLT1D1-1:9) GTGGCCAGATGAGGGT) chr12) 129597702)ENST_25_7) lnc-GLT1D1-1:9) TCCGTCAGAATGCACA) chr12) 129596019)ENST_25_8) lnc-GLT1D1-1:9) GATAATAGAGCAACTC) chr12) 129596099)ENST_25_9) lnc-GLT1D1-1:9) TTATATGGGAATTGGT) chr12) 129597731)ENST_25_10) lnc-GLT1D1-1:9) CTAGTAAAGATTACTG) chr12) 129596329)TCONS_59_1) lnc-FHL2-1:2) GCGTCCGTGAGCTGGG) chr2) 106217644)TCONS_59_2) lnc-FHL2-1:2) CGGGGAACACACGCAC) chr2) 106213655)TCONS_59_3) lnc-FHL2-1:2) CGGCTGGTGCAACAGG) chr2) 106217615)TCONS_59_4) lnc-FHL2-1:2) AGGACATGAAGGCGGA) chr2) 106217494)TCONS_59_5) lnc-FHL2-1:2) CAGCGTCCGTGAGCTG) chr2) 106217642)TCONS_59_6) lnc-FHL2-1:2) GTGCTGAGCTGTGCAA) chr2) 106213611)TCONS_59_7) lnc-FHL2-1:2) GGTGCAACAGGGGTCA) chr2) 106217620)TCONS_59_8) lnc-FHL2-1:2) TCGTATATAAAATAAC) chr2) 106215652)TCONS_59_9) lnc-FHL2-1:2) AAGAACTACGAATATT) chr2) 106217348)TCONS_59_10) lnc-FHL2-1:2) CGGATGAATGTACTTT) chr2) 106217506)lnc-RBM48-1) lnc-RBM48-1:4) GCGGCTCCCACATTCC) chr7) 92546293)lnc-RBM48-2) lnc-RBM48-1:4) GAAACCAGCCAGGGGT) chr7) 92484225)lnc-RBM48-3) lnc-RBM48-1:4) GCAGGGGTGAGACTTG) chr7) 92485084)lnc-RBM48-4) lnc-RBM48-1:4) TCTCCTAGGTGTTGCA) chr7) 92546228)lnc-RBM48-5) lnc-RBM48-1:4) GGCATATGATGCAGGG) chr7) 92485094)lnc-RBM48-6) lnc-RBM48-1:4) CAGGGGTGAGACTTGA) chr7) 92485083)lnc-RBM48-7) lnc-RBM48-1:4) CGGCTCCCACATTCCA) chr7) 92546292)lnc-RBM48-8) lnc-RBM48-1:4) GGCGCCACGCCCAGTC) chr7) 92500869)lnc-RBM48-9) lnc-RBM48-1:4) GCGTCTGGCAGGGGCC) chr7) 92527466)lnc-RBM48-10) lnc-RBM48-1:4) TGGGCACGGCATGGGC) chr7) 92510450)lnc-RBM48-11) lnc-RBM48-1:4) AGGCATCATCAGCGGC) chr7) 92546304)lnc-RBM48-12) lnc-RBM48-1:4) TTTTCACGGTGTGGCA) chr7) 92546447)lnc-RBM48-13) lnc-RBM48-1:4) CAGGCCCCCGGATGGC) chr7) 92510226)lnc-RBM48-14) lnc-RBM48-1:4) GACATCCTTGGAGAGG) chr7) 92485116)lnc-RBM48-15) lnc-RBM48-1:4) TGCGTGGGCTCTGCGA) chr7) 92505293)lnc-RBM48-16) lnc-RBM48-1:4) CGAATAATAAAATTCC) chr7) 92485009)lnc-RBM48-17) lnc-RBM48-1:4) TTAAGTATTATATGTC) chr7) 92496222)lnc-RBM48-18) lnc-RBM48-1:4) CCTTACTTTAATATAA) chr7) 92545541)lnc-RBM48-19) lnc-RBM48-1:4) TTTTGAGCTATCTAGG) chr7) 92485049)lnc-RBM48-20) lnc-RBM48-1:4) GGGTAAGATTATAATA) chr7) 92520172)lnc-DCTD-1) lnc-DCTD-7:3) GCTCCGGTTCAGGGCC) chr4) 181985563)lnc-DCTD-2) lnc-DCTD-7:3) CTCGGCCAGCTTTGGC) chr4) 181985549)lnc-DCTD-3) lnc-DCTD-7:3) GCCAGCTTTGGCTCCG) chr4) 181985553)lnc-DCTD-4) lnc-DCTD-7:3) TGGATTCGCTTGTCTG) chr4) 182076832)
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This!PhD! is!set! in!the!era!of!emerging! lncRNA!research.!Most! lncRNA!annotation! is!
very! recent;! consequently,! it! is! absent! from!popular!platforms!and!databases.! The!





and! a! consequence! of! recent! advances! in! deep! RNA! sequencing.! Yet,! the! rate! at!
which! they! find! their! way! to! the! genomic! reference! databases! such! as! Ensembl1,!
RefSeq2!and!UCSC3!is!much!lower!as!annotators!struggle!to!keep!up!or!hold!a!more!
conservative! position.! A! broad! collection! of! sequenced! lncRNAs! is! nonetheless!
invaluable! for!highVthroughput!transcriptomics.!We!developed!LNCipedia!to! fill! this!
gap! and! provide! extensive! and! meaningful! lncRNA! annotation! to! the! community.!
With! an! average!of!over! 100! visitors! every!day! (Figure!5),! about!500!emails! to! the!
authors! regarding! database! exports,! over! 100! citations! (Google! scholar)! for! the!
original! LNCipedia! paper! and! numerous! mentions! on! blogs! and! social! media,! we!
believe! LNCipedia! has! proven! to! be! a! relevant! resource! for! lncRNA! researchers.!
While! several! other! lncRNA! databases! such! as! NONCODE4,! LncRNA2Function5,!
DIANAVLncBase6!and!many!more!have!mushroomed!in!the!past!few!years,!LNCipedia!
holds!a!unique!position!as!the!largest!publicly!available!human!lncRNA!resource.!As!a!
result,! LNCipedia! has! been! recommended! as! a! primary! resource! in! a! 2014! review!
article!on!lncRNA!databases!due!to!its!compromise!between!coverage!and!depth!of!
annotations7.!The!catalogue!of!human! lncRNAs!however! is! far! from!complete!as! is!
our! understanding! of! the! transcriptome! in! general.! In! sharp! contrast! to! our! initial!
view!on!the!human!genome,!we!now!know!that!most!of!the!genome!is!transcribed!
into! distinct! RNA! transcripts8V10.! Even!more,! targeted! RNA! sequencing! of! selected!
genomic! loci! (CaptureSeq)! revealed! an! immense! uncharted! complexity! of! the!
transcriptome.! It! uncovers! extensive! alternative! splicing! both! in! and! outside! of!
annotated! loci! including!many! rare! isoforms11,12.! As! the! greater!majority! of! these!
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novel! transcripts! lack!signs!of!coding!potential,! it! is! reasonable! to!assume!that! the!
(long)! nonVcoding! transcriptome!will! continue! to! grow!over! the! coming! years.! The!
crucial!question!however!is!not!on!the!number!of!transcribed!nonVcoding!genes!but!
on! the! number! of! functional! nonVcoding! genes! in! the! genome.! Even! though! the!
number! of! lncRNAs!with! an! experimentally! derived! function! is! steadily! increasing,!
some! people! remain! skeptical! that! functional! lncRNA! genes! outnumber! protein!
coding! genes! in! the! human! genome13.! Often,! the! lack! of! measurable! sequence!
conservation!forms!the!basis!for!their!doubt.!Recently,!several!research!groups!have!
studied!lncRNA!evolution!and!have!each!identified!a!subset!of!conserved!lncRNAs14V
16.! Although! their! results! do! show! that! lncRNAs! are! more! recent! adaptations!
compared! to! most! protein! coding! genes,! they! are! clearly! subject! to! selective!
pressure! contrary! to! previous! suggestions.! In! LNCipedia,! we! apply! the! concept! of!
locus! conservation17! to! aid! the! identification! of! lncRNA! orthologs.! Yet,! locus!
conservation! alone! is! not! enough! to! prove! conservation! of! the! gene,! let! alone! its!
function.! In! a! future! release! of! LNCipedia,! we! will! therefore! incorporate! more!
relevant! measures! and! datasets! to! tackle! this! problem.! Since! most! research! on!



















































prediction! programs! (vide& supra).! In! LNCipedia,! we! include! several! of! these!
programs,! namely! CPC18,! HMMER19! and! PhyloCSF20,! and! our! analyses! show! poor!
coding! potential! for! the! greater! majority! of! lncRNAs.! Nevertheless,! a! substantial!
fraction! of! LNCipedia! transcripts! show! elevated! coding! potential! compared! to!
benchmarking! datasets.! It! is! important! to! note! however! that! while! benchmarking!
datasets!are!typically!composed!of! intergenic!nonVcoding!transcripts,!meaning!they!
do! not! overlap! with! protein! coding! sequence,! a! considerable! fraction! of! lncRNA!
transcript! overlaps! protein! coding! genes,! in! sense! or! antisense.! As! it! is! currently!
unclear!what!fraction!of!LNCipedia!corresponds!to!these!kinds!of!transcripts,!we!will!
look! into!subclassification!of! lncRNAs!according!to!their!relative!position!to!protein!
coding! genes! in! a! future! release! of! LNCipedia.! Further! analysis! on! the! coding!
potential!of!the! intergenic!subset!can!provide!a!better! insight! in!the!true!extent!of!
putative! protein! coding! genes.! While! several! research! groups! have! turned! to!
ribosome! profiling! as! a! method! to! distinguish! protein! coding! from! nonVcoding!
sequence,! interpretation! of! these! data! is! not! without! pitfalls! and! complications.!!
Consequently,!distinct!authors!have!come!to!contrary!conclusions!when!examining!
ribosome! occupancy! on! lncRNAs21,22.! Therefore,! we! and! other! groups! have! used!
shotgun!proteomics!data!to!detect!the!putative!products!of!lncRNA!ORFs.!Our!results!
show! that! only! a! minute! fraction! of! LNCipedia! lncRNAs! (<1.5%)! bears! ORFs! that!
produce! detectable! peptides.! This! is! very!much! in! agreement!with! similar! efforts,!
where!also!only!low!numbers!of!novel!peptides!were!found23V25.!These!low!numbers!












The! number! of! lncRNAs! that! produce! detectable! peptides! according! to! our! PRIDE!
reprocessing! pipeline! increased!drastically! (from!14! to! 2,040)! in! the! LNCipedia! 3.1!
release.!This!increase!can!be!attributed!to!both!the!increase!in!LNCipedia!entries!and!
the!increased!number!of!PRIDE!experiment!evaluated.!In!addition,!the!sources!that!





Bioinformatics! Institute! and! the! Wellcome! Trust.! The! goal! of! this! retreat! was! to!
gather! all!major! genetic! annotation! groups! and!devise! a! consensus! framework! for!
validation!of!novel!human!coding!loci.!
IV.2. LNCRNA!IN!CANCER!
Until! now! the! identification!of! new! cancer! associated! genes!by! largeVscale! genetic!
screening!of!cancer!samples!has!been!mainly!restricted!to!protein!coding!genes26,27.!
Nevertheless,! several! lncRNAs! have! been! implicated! in! cancer,! both! as! tumor!
suppressor! and! oncogene28.! To! identify! putative! novel! cancer! associated! lncRNA!
genes,! we! developed! a! unique! platform! to! detect! small! and! focal! copy! number!
aberrations! that! affect! lncRNA! exons! but! do! not! cover! protein! coding! genes.! The!
copy! number! profile! of! cancer! cells! has! often! been! used! to! identify! new! cancer!
associated! genes! among! protein! coding! genes29,30.! These! studies! clearly! show! the!
importance!of!the!size!of!the!aberration!as! larger!aberrations!cover!multiple!genes!
and! thus! prevent! the! clearVcut! identification! of! the! cancer! gene.! Our! strategy! is!
unique! since! our! probes! are! confined! to! narrow! genomic! loci! and! restricted! to!
lncRNA!exons!and!the!exons!of!their! flanking!protein!coding!genes.!As!a!result,!we!






reported! in! a! recent! largeVscale! RNA! sequencing! effort32.! In! addition,! our! list! of!
putative! cancer! genes! also! harbors! lncRNAs! that! have! previously! been! associated!
with! cancer! by! other! means,! further! demonstrating! the! validity! of! our! approach.!




and! the! discovery! of! novel! transcripts,! gene! expression! microarrays! offer! an!
economical! alternative! for! the! assessment! of! global! gene! expression! pattern! of!
known! transcripts.! Moreover,! RNA! sequencing! and! gene! expression! microarrays!
generally!show!good!concordance!and!it! is!only!at!high!sequencing!depth!that!RNA!
sequencing! outperforms! the! latter33.! Recently,! a! largeVscale! comparison! between!
RNA!sequencing!and!microarray!using!498!primary!neuroblastoma!samples!showed!
that! both! platforms! performed! equally! well! for! clinical! endpoint! prediction34.! As!
such,!we!designed!a!custom!gene!expression!microarray!based!on!Agilent’s!SurePrint!
G3! platform! to! measure! the! expression! of! LNCipedia! lncRNAs! and! mRNAs.! Our!
custom!array!and! its! successor!have!been!used!extensively!both!at! the!CMGG!and!
other!research!labs!over!the!past!few!years.!In!addition,!it!formed!the!basis!for!the!
development! of! the! latest! version! of! the! commercial! SurePrint! G3! platform! by!
Agilent!Technologies.!However,!as!RNA!sequencing!becomes!more!affordable,!gene!
expression! microarrays! will! no! longer! be! the! most! economical! alternative.!
Furthermore,! RNA! sequencing! yields!more! information.! It! is! thus! foreseeable! that!




research! and! antisenseVbased! tools! have! proven! to! be! valuable! for! this! purpose.!
Antisense!strategies!that!show!great!effectiveness!for!protein!coding!genes!however!
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may!be!unsuitable! for! lncRNAs! since! they!are! insensitive! to! inhibition!of! ribosome!
association! or! due! to! their! subcellular! localisation8.! While! siRNAs! have! been!
predominantly! used! to! achieve! transient! knockdown! of! lncRNAs,! our! work! shows!
great!potential! in!the!use!of!ASOs!for!this!purpose.!Random!selection!of!ASOs!with!
perfect! complementarity! to! a! lncRNA! target! of! interest! is! a! viable! option! for! ASO!
selection! although! the! success! rate! is! low.! Therefore,! we! constructed! an! in& silico!
model! to! predict! ASO! potency! based! on! thermodynamic! properties! and! the!
secondary! structure!of! the! target.! In! addition,!we!have! show! that! 2’VOVme!or! LNA!
gapmers! can! improve! the! stability! of! the! knockdown! and! reduce! the! required!
concentration.! Finally,! we! devised! a! strategy! to! select! and! evaluate! high! quality!




lncRNA!perturbation! remains! troublesome!and!often,! sufficient! knockdown!cannot!
be!achieved.!While!it!is!hard!to!assess!the!scale!of!this!problem!from!literature,!we!
have!learned!from!our!own!experience!and!contacts!with!other!research!groups!that!
in& vitro! perturbation! is! quite!often! the!most!difficult,! yet! critical! step! in! functional!
lncRNA!research.!For!that!reason,!several!research!groups!have!turned!to!genomeV
editing! to! create! stable! knockdown! cell! lines! or! model! organism.! Especially! the!
recently! developed! CRISPRVCas! systems! (Clustered,! Regularly! Interspaced,! Short!
Palindromic!Repeat)35!have!gained!the!attention!of!the!lncRNA!research!community.!
These! systems! are! based! on! the! bacterial! Cas9,! an! endonuclease! that! forms! a!
complex! with! specific! RNA! molecules! and! subsequently! cleaves! DNA! that! is!
complementary!to!these!RNA!molecules.!By!engineering!these!soVcalled!guide!RNAs!
(gRNAs)!with! complementarity! to!a!genomic! location!of! interest,! researchers!were!
able! to! perform! genomeVediting! in! a! wide! array! of! cell! types35.!While! for! protein!
coding!genes!a! small! genomic! change! can!be! sufficient! for! knockdown,! the! lack! in!




While! genomeVediting! using! CRISPRVCas! is! by! no! means! straightforward! and! its!






































































































Lange! nietVcoderende! RNAs! (lncRNAs)! vormen! een! nieuwe! klasse! van! genen! die!
talrijker! is!dan!eender!welke!andere!klasse! in!het!menselijk!genoom.!Aangezien!de!
meeste! lncRNA! annotatie! relatief! nieuw! is,! ontbreekt! deze! in! de! populaire!
databanken! en! op! commerciële! platformen.! Om! dit! probleem! aan! te! pakken!
verzamelde!ik!humane!lncRNA!annotatie!van!diverse!bronnen!en!ontwikkelde!ik!de!
publieke!lncRNA!databank!LNCipedia!(www.lncipedia.org)!in!de!eerste!maanden!van!
mijn! doctoraat.! Ondertussen! is! het! een! referentiedatabank! geworden! met! vele!
citaties! en! vermeldingen! in! het! lncRNA!onderzoeksveld.! Aangezien! het! debat! over!
het! werkelijke! aantal! nietVcoderende! lncRNAs! nog! steeds! gaande! is,! heb! ik!
bijzondere! aandacht! besteed! aan! het! bepalen! van! het! coderend! potentieel! van!
lncRNAs.!In!samenwerking!met!andere!onderzoeksgroepen!van!de!Universiteit!Gent!
heb! ik! een! strategie! bedacht! om! lncRNAs! met! coderende! open! leesramen! te!
detecteren! ! aan! de! hand! van! grote! publieke!massaspectrometrie! datasets.!Op! die!
manier!heb!ik!LNCipedia!kunnen!optimaliseren!en!kunnen!aantonen!dat!slechts!een!





Genetica! Gent! en! is! reeds! gebruikt! om! meer! dan! 1000! stalen! te! profileren.! Het!
tweede! platform! dat! ik! ontwikkelde! is! een! DNA! microarray! met! als! doel! kleine,!
focale!copynumbervariaties! te!detecteren!die! specifiek! lncRNAs!aantasten.!Met!dit!
platform! heb! ik! het! DNA! van! 80! kankercellijnen! bestudeerd! en! een! groot! aantal!
lncRNAs! met! een! potentiele! rol! in! kanker! ontdekt.! Om! lncRNAs! in& vitro! te!
bestuderen! hebben! we! technieken! nodig! waarmee! we! de! genexpressie! kunnen!
manipuleren.! Daarom! evalueerde! ik! de! bruikbaarheid! van! antisense!







Long! nonVcoding! RNAs! (lncRNAs)! form! a! new! class! of! genes! that! outnumbers! any!
other!class!of!RNAs!predicted!in!the!human!genome.!Since!most!lncRNA!annotation!
is! relatively! new,! lncRNAs! are! underrepresented! in! the! established! genomic!
databases! and! on! the! commercially! available! platforms.! To! address! this! issue,! I!
collected!human!lncRNA!annotation!from!different!sources!and!developed!the!public!
lncRNA!database!LNCipedia!(www.lncipedia.org)!in!the!first!months!of!my!PhD.!Since!
then! it! has! become! a! reference! database! with! numerous! citations! and! mentions!
throughout! the! lncRNA! research! field.! As! the! debate! on! the! number! of! true! nonV
coding! lncRNAs! is!still!ongoing,! I!paid!particular!attention!to!the!assessment!of!the!
coding!potential!of!LNCipedia! lncRNAs.! In!collaboration!with!other!research!groups!
at!Ghent!University,! I!devised!a!strategy!to!use! large!public!proteomics!datasets!to!
detect! lncRNAs! with! coding! ORFs.! In! doing! so,! I! have! optimized! the! LNCipedia!
dataset! and! showed! that!only!a! small! number!of! lncRNAs!have! coding!ORFs.!With!
the!LNCipedia!catalogue!at!hand,!I!was!able!to!design!several!platforms!to!study!the!
functional!role!of!lncRNAs.!One!such!platform!consists!of!a!custom!gene!expression!





Using! this! platform,! I! screened! a! panel! of! 80! cancer! cell! lines! and! revealed! a! vast!
number! of! putative! cancer! associated! lncRNA! genes.! To! enable! in& vitro! lncRNA!
studies,! means! to! perturb! their! gene! expression! are! indispensable.! Therefore,! I!
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